CI N R Y Z E/ P R O T O C O L 0 6 2 4 -3 0 1 
( C o m p o u n d N u m ber V P 2 0 6 2 4) 
A P H A S E 3, M U L TI C E N T E R, R A N D O MI Z E D, SI N G L E -B LI N D , D O S E -R A N GI N G, 
C R O S S O V E R S T U D Y T O E V A L U A T E T H E S A F E T Y A N D E F FI C A C Y O F 
I N T R A V E N O U S A D MI NI S T R A TI O N O F CI N R Y Z E ®( C 1 E S T E R A S E I N HI BI T O R 
[ H U M A N]) FO R T H E P R E V E N TI O N O F A N GI O E D E M A A T T A C K S I N C HI L D R E N 
[ADDRESS_76820] a C T N u m ber 2 0 1 3- 0 0 2 4 5 3 - 2 9 
S hire VI R O PH A R M A IN C O R P O R A T E D 
3 0 0 S hire Wa y 
Le xi n gt o n , M A   0 2 4 2 1- 2 1 0 1 
U S A 
M E DI C A L M O NI T O R 
, M D, F R C P( C) 
Office p h o ne:  
M o bile p h o ne: 
E mail:  
Ori gi n al D ate:   [ADDRESS_76821] 2 0 1 3 
A m e n d me nt 1:   [ADDRESS_76822] o ber 2 0 1 3 
A m e n d me nt 2:   1 1 Dece m ber 2 0 1 3 
A m e n d me nt 3:   0 2 J u ne 2 0 1 4 
A m e n d me nt 4:   2 6 Ja n uar y  2 0 1 5 
C O N FI D E N TI A LI T Y S T A T E M E N T 
T his d oc u me nt is t he c o nfi de ntial pr o pert y of S hire VI R O PH A R M A IN C O R P O R A T E D 
(Vir o P har ma a n d its affiliates are w h oll y -o w ne d s u bsi diaries of S hire plc) .  N o part of it ma y  
be tra ns mitte d, re pr o d uce d, p u blis he d, or use d b y ot her pers o ns wit h o u t pri or writte n 
a ut h orizati o n fr o m S hire VI R O PH A R M A P P D 
.P P D P P D 
P P D 
C!NRYZE®(Cl esterase inhibitor [human]) 
Protocol 0624-[ADDRESS_76823] NAME (CODE): CINRYZE (VP [ZIP_CODE]) 
Title: A PHASE 3, MULTICENTER, RANDOMIZED, SINGLE-BLIND, DOSE-RANGING, 
CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 
INTRA VENOUS ADMINISTRATION OF CINRYZE® [C1 ESTERASE INHIBITOR 
(HUMAN)] FOR THE PREVENTION OF ANGIOEDEMA ATTACKS IN CHILDREN 6 TO 
11 YEARS OF AGE WITH HEREDITARY ANGIOEDEMA 
DEPARTMENT 
Clinical Operations 
Regulatory Affairs 
Medical Monitor/ 
Clinical Research 
26 January 2015 26 January 2015 
NAME 
, MS 
, MBA 
, MD, 
FRCP(C) 
2 DATE 
CONFIDENTIAL 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
CINRYZE® (C1esterase inhibitor [human])
Protocol [ADDRESS_76824] OF ABBREVIATIONS AND DEFINITIONS OF TERMS ...........................................6
AMENDMENT 4:  26 JANUARY 2015 ..................................................................................8
AMENDMENT 3:  02 JUNE 2014 .........................................................................................11
AMENDMENT 2:  11 DEC EMBER 2013
.............................................................................13
AMENDMENT 1:  [ADDRESS_76825]
OBER 2013 ................................................................................14
PROTOCOL  SYNOPSIS ........................................................................................................16
SCHEDUL E 1: CLINICAL STUDY ASSES SMENTS –SCREENI NG AND 
BASELINE OBSERVATION PERIOD .........................................................25
SCHEDUL E 2: CLINICAL STUDY ASSES SMENTS 
–TREATMENT PERI OD 1 .....26
SCHEDUL E 3: CLINICAL STUDY ASSES SMENTS 
–TREATMENT PERI OD 2 .....28
SCHEDUL E 4: CLINICAL STUDY ASSES SMENTS – EARLY 
DISCONTINU ATION, 1-WEEK POST -TREATMENT, AND 1-MONTH 
POST -TREATMENT FOLLOW -UP VI SITS................................................30
SCHEDUL E 5: BLOOD SAMPLE COLLECT ION FOR PK/PD AND PO
ST-
TREATMENT IMMUNOGENI CITY ASSESSMENTS ...............................31
1.0 INTRODUCTION ...........................................................................................32
1.1 CINRYZE® (C1 esterase inhibitor [human]) ...................................................33
1.1.1 Nonclinical Experience with I ntravenous Administration ..............................34
1.1.2
Clinical Experience with Intravenous Administration ....................................34
1.1.3 Pediatric Experience with I ntravenous Administration ................................ ...36
1.2 Study  Rationale ................................................................................................42
2.0 STUDY OBJECTIVES ................................ ................................ ................... 44
3.0 INVESTIGATIONAL PLAN ..........................................................................44
4.0 STUDY POPUL ATION..................................................................................49
4.1 Inclusion Criteria
................................ ................................ ............................. 49
4.2 Exclusion Criteria ................................ ................................ ............................ 50
5.0 STUDY DRUG ADMINISTR ATION ................................ ............................ 50
CINRYZE® (C1esterase inhibitor [human])
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
TABLE OF CONTENTS Page
26 January 2015 4 CONFIDENTIAL5.1 Dose Selection ................................ ................................ ................................ .50
5.2 Randomization .................................................................................................51
5.3 Study  Drug .......................................................................................................51
5.4
Blinding ...........................................................................................................52
5.5
Stoppi[INVESTIGATOR_1869].................................................................................................52
5.5.1 Anaph ylactic Reaction .....................................................................................52
5.5.2
Thrombotic or Thromboembolic Event...........................................................53
6.0
STUDY PROCEDURES.................................................................................53
6.1 Medical History  and Physical Examination ....................................................53
6.1.1 HAE History ....................................................................................................54
6.2 Vital Signs .......................................................................................................55
6.3 Prior and Concomitant Medications ................................................................55
6.3.1 Prior Medications
.............................................................................................55
6.3.2 Concomitant Medications ................................................................................56
6.3.3
Prohibited Medications....................................................................................56
6.4 Nonpharmacologic Treatments and Procedures ..............................................56
6.5 Clinical L aboratory  Parameters .......................................................................56
6.6 Pharmacokinetic, Pharmacod ynamic, and C1 INH Antibody  Anal yses.........57
6.7 Total Blood Volume Collected ........................................................................58
6.8 Restrictions ......................................................................................................59
6.9 Electronic Study  Diary  (eDiary )
......................................................................59
6.10 Angioedema Attacks ........................................................................................60
6.10.1 Recording of Angioedema Attacks ..................................................................60
6.10.2 Management of Acute Angioedema Attacks ...................................................61
6.10.3 Angioedema A ttacks During Treatment Periods .............................................61
6.11 Quality  of Life Measurements .........................................................................62
6.11.1 Health
-related Quality  of L ife (EQ-5D-Y)................................ ...................... 62
6.12 Discontinuation From Treatment and/or Study ...............................................62
6.12.1 Discontinuation From Treatment .....................................................................63
6.12.2 Discontinuation From Study ................................ ................................ ............ 64
7.0 STATI STICAL METHODOL OGY ................................ ................................ 64
7.1 Sample Size .....................................................................................................64
7.2 Populations ................................ ................................ ................................ ......64
7.3 Efficacy  Anal ysis................................ ................................ ............................. 65
7.4 Safety  Anal ysis................................ ................................ ................................ 66
CINRYZE® (C1esterase inhibitor [human])
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
TABLE OF CONTENTS Page
26 January 2015 5 CONFIDENTIAL7.5 Other Endpoints ................................ ................................ ............................... 66
7.6 Pharmacokin etic and Pharmacod ynamic Anal yses.........................................66
8.0 DRUG SUPPLIES ...........................................................................................67
8.1
How Supplied ..................................................................................................67
8.1.1 Reconstitution of CI NRYZE for Intravenous Infusion ...................................67
8.2 Drug Accountability ........................................................................................68
8.3 Drug Labels .....................................................................................................68
9.0 ADVERSE EVENTS ......................................................................................68
9.1 Severity  (Intensit y) Assessment ......................................................................[ADDRESS_76826] CONFIDENTIAL
ITY ...................................................................74
14.0 INFORMED CONSENT .................................................................................74
15.0 INDEPENDENT REVIEWI NG AUTHORITY APPROVAL .......................75
16.0 PUBLICATION POLICY ...............................................................................76
17.0 INVESTIGATOR'S STATE
MENT (PROTOCOL 0624 -301) .......................[ADDRESS_76827] OF REFERENCES .................................................................................79
APPENDIX I: PROCESSI NG OF SAMPL ES FOR ANALYSES OF C1INH ANTIGEN, 
C1 INH FUNCTION, C4COMPL EMENT, AND C1INH 
ANT IBODIES 
IN HUMAN PLASMA ....................................................................................82
APPENDIX II: RECOMMENDED PROCEDUR ES FOR SUSPECTED VEN OUS 
THROMBOEMBOLISM OR OTHER THROMBOTIC OR 
THROMBOEMBOLIC EVENT
S...................................................................84
CINRYZE® (C1esterase inhibitor [human])
Protocol [ADDRESS_76828] Aspartate aminotransferase
AUC Area under the plasma concentration -versus -time curve
AUC 0- Area under the plasma concentration -versus -time curve from time 0 to in finity
AUC 0-τArea under the plasma concentration -versus -time curve from time 0 to selected 
time point
BMI Body  mass index
BP Blood pressure
BUN Blood urea nitrogen
C Centigrade
C1 INH C1 esterase inhibitor or C1 inhibitor
Cavg Average concentration at steady state
CBC Com plete blood count
CHO Chinese hamster ovary
CL Clearance
CL/F Apparent plasma clearance
Cmax Maximum concentration
Cmin Minimum concentration
CO [ADDRESS_76829] Com puter axial tomography
CTA Clinical Trial Agreement
DC Discontinuation
DNA Deoxyribonucleic acid
DVT Deep venous thrombosis
ECG Electrocardiogram
eCRF Electronic case report form
eDiary Electronic study diary
EDTA Ethylenediami netetraacetic acid
ER Emergency room
EU European Union
F Fahrenheit; Bioavailability 
FDA Food and Drug Administration
h, hr Hour(s)
HAE Hereditary angioedema
HIV Human immunodeficiency virus
HR Heart rate
ICH International Conference on Harmonisa tion
ID Intradermal
IEC Independent Ethics Committee
INR International normalized ratio
IRA Independent Reviewing Authority (e.g., Institutional Review Board or 
Independent Ethics Committee)
CINRYZE® (C1esterase inhibitor [human])
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 7 CONFIDENTIALAbbreviation Definition
ISR Incurred sample reproducibility
ISS Incurred sample sta bility
ITT-E Intent -to-Treat Efficacy (population)
ITT-S Intent -to-Treat Safety (population)
IUD Intrauterine device
IV Intravenous
IXRS Interactive voice and web response system
Kel Elimination rate constant
MedDRA Medical Dictionary for Regulatory Activities
mM Millimolar
mOsmol Milliosmole
n, N Sample size
NA Not applicable
NDA New  Drug Application
PD Pharm acody namic(s)
PE Pulmonary embolism
PEG Polyethylene glycol
Ph. Eur. European Pharmacopeia
PK Pharm acokinetic(s)
PT Prothrombin time
QoL Quality of life
RBC Red blood cells
Rmax Maximum pharmacodynamic response
RSI Reference safety information
SAE Serious adverse event
SC Subcutaneous
SD Standard deviation
SOP Standard operating procedure
SPC, SmPC Summary of Product Characteristics
S[LOCATION_003]R Suspected unexpected serious adverse reaction
SWFI Sterile water for injection
T/TE Thrombotic/thromboembolic
t1/2 Term inal elimination half -life
TEAE Treatment- emergent AE
tmax Time to maximum concentration or maximum pharmacodynamic r esponse
TX Treatment
U Unit(s)
US [LOCATION_002]
USP [LOCATION_002] Pharmacopeia
USPI [INVESTIGATOR_70520]
V/Q Ventilation/perfusion scan
VTE Venous thromboembolism
Vz/F Apparent volume of distribution
WBC White bl ood cell
WHO World Health Organization
NOTE: Table includes comprehensive list of abbreviations used in CINRYZE regulatory documents.
CI N R Y Z E ® ( C 1 esterase i n hi bit or [h u ma n] )
Pr ot oc ol 0 6 2 4 -3 0 1 w it h A me n d me nts 1 , 2, 3, a n d 4 
2 6 Ja n uar y 2 0 1 5 8 C O N FI D E N TI A L A M E N D M E N T 4: [ADDRESS_76830] u d y  r e p ort will ser ve as t he basis f or a re g ulat or y 
s u b missi o n t o satisf y  t he E U Pe diatric I n vesti gati o n Pla n .  I n  a d diti o n, te xt has bee n a d de d t o 
Secti o n 3. 0 
P P D (I n vesti gati o nal Pla n) , t o all o w t he fle xi bilit y  o fa d di n g c o u ntries or re gi o ns if 
necessar y  t o c o m plete e nr oll me nt.   T his a me n d me nt als o i nc or p orates A d mi nistrati ve 
Re visi o n 1 ( date d 25Se pte m ber 2 0 1 4) w hic h u p date d t he pr ot oc ol title pa ge wit h t he c o ntact 
i nf or mati o n of t he ne w me dical m o nit or ( , M D) f or t his st u d y .
1. St u d y  Dr u g A d mi nistrati o n: 
E ur o pea n I n vesti gat ors rec o m me n de d re visi n g t he pr ot oc ol la n g ua ge t o all o w m ore fle xi bilit y 
re gar di n g st u d y  d r u g a d mi nistrati o n . A me n d me nt 3 s pecifies t hat CI N R Y Z E treat me nts will 
be pre pare d a n d a d mi nistere d b y  q ual ifie d site pers o n nel or q ualifie d h o me healt hcare 
pr ofessi o nals. P h y sicia ns ha ve s hare d t heir e x perie nce i n t he pe diatric p o p ulati o n a n d ha ve 
i n dicate d t hat pe diatric patie nts a ge d 6- 1 1 w h o t he y  s ee i n r o uti ne practice ofte n self -
a d mi nister (after trai ni n g) or ha ve a pare nt ad mi nister C 1 I n hi bit or ( C 1 I N H) treat me nt (after 
trai ni n g) . T hese I n vesti gat ors ha ve i n dicate d t hat pe diatric patie nts w h o c urre ntl y self -
a d mi nister , or w h o are r o uti nel y a d mi nistere d treat me nt b y  a n o n- healt hcare pr ofessi o nal 
(e. g., pare nt), will n ot a gree t o e nter a st u d y  r e q uiri n g t hat st u d y  site pers o n nel or h o me 
healt hcare pr ofessi o nals a d mi nister t he treat me nt f or t h est u d y .
T heref ore, Ame n d me nt 4 i nc or p orates t he f oll o wi n g c ha n ges :
-Clarifies t hat h o me healt hcare pr ofessi o nals ma y pre pare st u d y  d r u g at t he s u bject ’s 
h o me .
-All o w sself -a d mi nistrati o n of st u d y  d r u g f or s u bjects w h o self -a d mi nister C [ADDRESS_76831] u d y  d r u g b y  t rai ne d n o n- healt hcare pr ofessi o nals (e. g. ,
pare nt, le gal g uar dia n )f or s u bjects i n w h o m t his occ urs i n r o uti ne practice a n d w here 
t he prefere nce is t o c o nti n ue t o d o s o . If a n o n- healt hcare pr ofessi o nal (e. g. ,pare nt, 
le gal g uar dia n) w h o d oes n ot r o uti nel y  a d mi nister C 1 I N Hw o ul d li ke t o be gi n t his 
practice, it will be per mitte d a n d a p pr o priate trai ni n g will be pr o vi de d b y t he site .  
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 9 CONFIDENTIALRegardless of self-administration or administration by a non-healthcare professional, all 
study  drug will be administered under the supervision of qualified healthcare personnel
(i.e.,if study  drug is self -administer ed, or administered by  a non-healthcare professional, a 
qualified healthcare profess
ional will alway s be present ). Investigators will use their 
clinical judgment and knowledge of the home situation to determine whether self-
administration or administration by a non-healthcare professional is in the best interest of 
the pediatric subject.   
Added text is bolded and deleted text is struck through , as applicable.
All protocol sections affected by [CONTACT_70535], and the synopsis and 
schedules of procedures have been updated accordingl y.
3.0 INVESTIGATIONAL PLAN
This multicenter, randomized, single -blind, dose-ranging, crossover study  will be conducted 
in multiple countries including the US, EU, and Latin America. Other countries /regions
may be added if necessary to complete enrollment.
Subjects and parents/caregivers will be blinded to treatment sequence and dose.  Study  site 
personnel, qualified home healthcare professionals, and the Sponsor will not be blinded to 
treatment assignment and the dose of study  drug administered. Study  drug will be prepared 
and administered intravenously  by [CONTACT_70536], or by 
[CONTACT_70537]’s home or other agreed upon location.  
Alternativel y, if allowed per local regulations, subjects who have been trained to self-
administer C1 INH or who have a non-healthcare provider (e.g.,parent) who has been 
trained to administer C1 INH will be permitted to do so based upon the request of the 
subject (and with approval of the parent(s)/legal guardian and the Investigator.  Note: 
self-administration will always occur under the supervision of a qualified healthcare 
professional at the study site or the subject’s home (or other agreed upon location).
Super vision by a qualified healthcare professional will include real time direct visual 
observation of the following: selection of the injection site, preparation of the injection 
site, insertion of the infusion device into the vein, study drug infusion, remova l of 
infusion device, compression and applying a bandage to the injection site, and disposal 
of all infusion materials.
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76832] the parent/caregiver by 
[CONTACT_70538] (Week 3 after Dose 6 [Visits 6a and 6b] and 
Week 9 after Dose 18 [Visits 18a and 18b]).
5.[ADDRESS_76833]’s home. Alternatively ,if allowed per local regulations, subjects 
who have been trained to self-administer C1 INH or who have a non-healthcare 
provider (e.g., parent) who has been trained to administer C1 INH will be permitted to 
do so based upon the request of the subject (and with approval of the parent(s)/legal 
guardian and the Investigator ).  Note: self-administration will always occur under the 
supervision of a qualified healthcare professional at the study site or the subject’s home 
(or other agreed upon location). Supervision by a qualified healthcare professional will 
include real time direct visual observation of the following: selection of the injection site, 
preparation of the injection site, insertion of the infusion device into the vein, study drug 
infusion, removal of infusion device, compression and applying a bandage to the 
injection site, and disposal of all infusion materials.
7.[ADDRESS_76834] 6 subjects .  Safety,
efficacy and pharmacokinetic results will be reviewed, summarized and presented in a 
clinical study report.  This study report will serve as the basis for a 
regulatory 
submission to satisfy the EU Pediatric Investigation Plan .  A final CSR will be completed 
after 12 subjects finish the study.
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 11 CONFIDENTIALAMENDMENT 3:  02JUNE 2014
Amendment 3 to Protocol 0624-301 incorporates 2revisions:  
1.European Investigators recommend ed that a modification be made to the angioedema 
attack criteria qualify ingsubjects for study  inclusion.  Physicians may opt to provide 
early intervention with acute treatment when the attack is considered mild to minimize 
the risk of subsequent complicat ions with ongoing severit y.  Therefor eto allow 
angioedema attacks that require acute treatment to qualify , inclusion criteria #3 and #[ADDRESS_76835] a history  of ≥1.0 angioedema attacks per month (average) that are
moderate1or severe2orrequire acute treatment3angioedema attacks per 
month (average) during the 3 consecutive months prior to screening.
Additional Inclusion Criteria (Qualifying for Randomization)
6.Have experienced ≥1.0 angioedema attacks per month (average) that are
moderate1or severe2orrequire acute treatment3angioedema attacks per 
month (average) during the 12 -week baseline observation period.
                                                
1Moderate:  Angioedema attack sign/symptom(s) interferes with the subject’s ability to attend school or 
participate in family life and social/recreational activities.
2Severe:  Angioedema attack sign/symptom(s) significantly limits the subject’s ability to attend school or 
participate in family life and social/recreational activities.
3‘Treatment’ refers specifically to standard of care therapi[INVESTIGATOR_70521] (e.g., 
C1INH, kallikrein inhibitor, bradykinin receptor antagonist).  Products used for the treatm ent of attack 
symptoms (e.g., analgesics, anti -emetics) do not qualify for this study inclusion criterion.
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 12 CONFIDENTIALSection 6.6, Pharmacokinetic, Phar macodynamic, and C1 INH Antibody Analyses
NOTE:   If a subject presents to the site with an angioedema attack, every  effort should be 
made to obtain a PKblood sample prior to any  treatment.  In addition, if the subject is treated 
with commercial C1 INH, every effort should be made to obtain a 1-hour post-treatment 
sample .  These samples will be analyzed for C1INH antigen and functional C1INH 
activity.
Other administrative revisions (e.g., updating Sponsor’s contact [CONTACT_3031]) and editorial 
revisions have been made throughout the protocol for consistency .
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 13 CONFIDENTIALAMENDMENT 2:  11DECEMBER 2013
Amendment 2 to Protocol 0624 -301 encompasses t hree revisions.  Added text is bolded and 
deleted text is struck through, as applicable .
Exclusion Criterion 
#7 (Synopsis and Section 4.2),has been revised since some of the 
temperature conversions were incorrect :
7.Have any active infectious illness or fever defined as an oral temperature 
>38C (100.4 F) tympanic >38.5 C (101. 23F), axillary  >38.1C (100. 6F) 
or rectal/core >398.5C (101. 23F) within [ADDRESS_76836] dose of 
study  drug in Treatment Period 1. 
In Section 8.[ADDRESS_76837] label :
The US sourced vials of CINRYZE and SWFI will be stored at 20oC–25oC (68oF–
77oF)2oC–25oC (36oF–77oF)in the original carton and protected from light.  Do 
not freeze.
Appendix I (Reconstitution of CINRYZE) and all references throughout the protocol 
to this Appendix have been removed.  Subsequent appendices were renumbered.  
Instructions for the reconstitution of CINRYZE will be detailed in a separate 
Pharmacy  Manual.  
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 14 CONFIDENTIALAMENDMENT 1:  09 OCTOBER 2013
Amendment 1 to Protocol 0624- 301 encompasses nine substantive revisions:
In Schedule 3(Clinical Study  Assessments 
–Treatment Period 2), footnote “h” has 
been added to clarify  that if an angioe dema attack is ongoing at Visit 24b, then 
recording of signs and symptoms and completing the EQ-5D-Y should continue daily  
in the eDiary  until the attack resolves.
In Schedule 5(Blood Sample Collection for PK/PD and Post-treatment 
Immunogenicit y Assessments), two blood sampling time points have been corrected; 
the 
Post-dose time point was incorrectl y noted as Dose 1 rather than Dose 12.
Treatment Period 1 –Visit 12a / Dose [ADDRESS_76838] Dose 12(± 15 min)
Treatment Period 2 –Visit 12b / Dose [ADDRESS_76839] Dose 12(± 15 min)
In the Synopsis, Section 6.9(Electronic Study  Diary), and Section 6.11.1 (Health -
related Quality  of Life), text has been revised to state that the EQ-5D-Y (QoL 
assessment) is to be completed by [CONTACT_70539], as was 
stated in the original protocol.  The EQ-5D- Y is designed to be a self-reported 
questionnaire for children and adolescents.
In the Synopsis and Section 6.10 (Angioedema Attacks) , the definition of an 
angioedema attack has been revised to clarify  that there must be a “full symptom-free 
calendar day” preceding the onset of symptoms for an attack to be considered a new 
attack.  The original protocol stated that there was to be a “24-hr symptom -free 
interval”, however only the date (not time) ofsymptom onset and resolution for an 
angioedema attack is to be recorded .
In Sections 3.0(Investigational Plan), 6.9(Electronic Study  Diary), and 6.11.1
(Hea lth-related Quality  of L ife), information about integration of eDiary /QoL  data into 
the eCRF has been deleted; details about handling of these data will be provided in a 
separate Data Management Plan.
In Section 6.3.2 (Concomitant Medication), the requirement for study  personnel to 
record the start and stop “time” of medications administered in the management of 
angioedema attacks has been deleted.
In Section 6.9(Elec tronic Study  Diary), the details onallquestions contained 
withinthe eDiary have been deleted.  Instead there is a general high level 
description of the information to be collected and the responsibility  of the 
parent/caregiver and subject 
to complete this information in the eDiary . At the 
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76840] subjects and parents/caregivers how 
to complete the eDiary .
In Section 6.10.1 (Recording of Angioedema Attacks), “Other (descr ibe)” has been 
deleted as option for the location (site) of the swelling or pain associated with an 
angioedema attack. 
In Section 6.12 (Discontinuation From Treatment and/or Study ), the sentence referring
to the possibility  of enrolling additional subjects to replace subjects who withdraw or 
discontinue has been removed.  This referred to a scenario when the plan was to enroll 
a sufficient number of subjects (8) to ensure that [ADDRESS_76841] been made to the schedules of clinical assessments to clarify 
study  procedures and also throughout the protocol for consistency  with the nine revisions 
noted above.   In addition, CINRYZE recentl y received marketing authorization in Israel 
(August 2013); this information has been added to Section s 1.1and1.2.
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 16 CONFIDENTIALPRO TOCOL SYNOPSIS
Study Title:   A phase 3,multicenter, randomized, single -blind , dose -ranging, crossover study 
to evaluate the safet y and efficacy  of intravenous administration of CINRYZE®(C1esterase 
inhibitor [human]) for the prevention of angioedema attacks in children 6 to 11years of age 
with hereditary  angioedema (Protocol 0624 -301). 
Study Objectives:   
Primary  Objective
To assess the relative efficacy  of two dose levels of CINRYZE (500 U and 
1000 U) administered by [CONTACT_33980] (IV) injection every  3 or 4 daysto prevent 
angioedema attacks in children 6 to 11 y ears of age.
Secondary  Objectives
To asses s the safety  and tolerability  of two dose level s of CINRYZE administered 
by [CONTACT_70540] 6 to 11years of age with hereditary  angioedema 
(HAE) .
Tocharacterize the pharmacokinetics (PK) and pharmacod ynamics (PD) of 
CINRYZE administered by  [CONTACT_70540] 6 to 11 years of age .
To assess the immunogenicity  of CINRYZE following IV administration.
Other Objective
To assess theimpact of treatment onhealth status (quality  of life) in children 6 to 
11 years of age with HAE .
Study Population :  
Number of Subjects
Twelve subjects will be randomized in this study .  
Inclusion Criteria
To be eligible for this protocol, a subject must:
1.Bea child (male or female), ≥6 to <[ADDRESS_76842] a functional 
C1inhibitor (C1 INH) level less than 50% of normal.
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76843] a history of ≥1.0 angioedema attacks per month (average) that are moderate1
or severe2or require acute treatment3during the [ADDRESS_76844] a parent(s)/legal guardian who is informed of the nature of the study  provide 
written informed consent for the child to participate in the study  before any study-
specific procedures are performed (with assent from the child when appropriate).  
Additional Inclusion Criteria (Qualifying for R andomization )
6. Have experienced ≥1.0 angioedema attacks per month (average) that are moderate1
or severe2or require acute treatment3during the 12-week baseline observation 
period.
Exclusion Criteria
To be eligible for this protocol, a subject must not:
1.Have a history  of hy percoagulabi lity (abnormal blood clotting).
2.
Have a diagnosis of acquired angioedema or known to have C1 INH antibodies.
3.Have a history  of allergic reaction to C1 INH products, including CINRYZE (or 
any of the components of CI NRYZE), or other blood products.
4.Be pregnant or breastfeeding. 
5.Have received an investigational drug other than those required for prevention or 
treatment of angioedema attacks within [ADDRESS_76845], as determined by [CONTACT_2725]’s medical monitor, any 
surgica l or medical condition that could interfere with the administration of study  
drug or interpretation of study  results.
Additional Exclusion Criteria ( Disqualifying from Randomization)
7.Have any active infectious illness or fever defined as an oral temperatur e >38C
(100.4
F), tympanic >38.5 C (101.3 F), axillary  >38C (100.4 F), or rectal/core 
>38.5 C (101.3 F) within [ADDRESS_76846] dose of study  drug in 
Treatment Period 1. 
                                                
1Moderate:  Angioedema attack sign/symptom(s) interferes with the subject’s ability to attend school or 
participate in family life and social/recreational activities.
2Severe:  Angioedema attack sign/symptom(s) signifi cantly limits the subject’s ability to attend school or 
participate in family life and social/recreational activities.
3‘Treatment’ refers specifically to standard of care therapi[INVESTIGATOR_70521] (e.g., 
C1INH, kallikrein inhibitor, bradykinin receptor antagonist).  Products used for the treatm ent of attack 
symptoms (e.g., analgesics, anti -emetics) do not qualify for this study inclusion criterion.
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76847] dose of study drug in Treatment Period 1.
Duration of Study:   Individual participation from screening through the completion of 
1-month safet y follow - upvisit will beapproximately  10 months ( 1 -day screening visit, 
12-week baseline observation period, two 12- week treatment periods [consecutive without 
any washout between treatment periods] , and [ADDRESS_76848]-treatment safety  follow -upvisit).  
Drug Product: CINRYZE is supplied as a lyophilized powder of 500 Units (U) C1 INH per 
vial.  Each vialof CINRYZE will be reconstituted for IV infusion with 5 mL of sterile water.  
Each infusion will require reconstitution of one (1) or two (2) 500 U vials depending on the 
treatment scheduled (Treatment A [500 U] or Treatment B [1000 U]).  The solution must be 
used within 3 hours of reconstitution.
Study Drug Administration:   CINRYZE (500 U or 1000 U) will be administered by [CONTACT_70541]  (every  3 or 4 days) for 12weeks in two crossover treatment periods.  
Study  drug will be administered intravenously by [CONTACT_70542] a location outside of the investigative site (e.g., home ).Alternativel y,
if allowed per local regulations, subjects who have been trained to self-administer C1INH or 
who have a non-healthcare provider (e.g.,parent) who has been trained to administer C1INH 
will be permitted to do so based upon the request of the subject (and with approval of the 
parent(s)/legal guardian and the Investigator )
.  Note: self-administration will always occur 
under the supervision of a qualified healthcare professional at the study  site or the subject’s 
home (or other agreed upon location). Supervision by  a qualified healthcare professional will 
include real time direct visual observation of the following: selection of the injection site, 
preparation of the injection site, insertion of the infusion device into the vein, study  drug 
infusion, removal of infusion device, compression and apply ing a bandage to the injection 
site, and disposal of all infusi on materials.
Treatment Sequences:   Participants in this crossover study  are expected to receive both 
treatments (A = 500 U and B = 1000 U), assigned in random order, in sequential treatment 
periods.  Each treatment period will be 12 weeks , without a washo ut between the two periods.  
Eligible subjects will be randomized to one of two treatment sequences , A/B or B/A.
Study Design: This multicenter, randomized, single -blind , dose-ranging, crossover study 
will be conducted in multiple countries including the [LOCATION_002], Europe and Latin
America .  Other countries /regions may be added if necessary  to complete enrollment.
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 19 CONFIDENTIAL
Potential subjects (≥6 to <12 years of age) will have a screening evaluation the day prior to 
entering the study ’s baseline observation period.  Subjects with qualify ing angioedema attack 
rates, and who meet all other eligibility  criteria, will be enrolled and enter theobservation 
period for at least 12 weeks .  
Throughout the study , an electronic study  diary (eDiary ) will be used to collec t specific 
information regarding the subject’s symptoms of HAE.  The eDiary  will consist of two 
sections:  
(a) Section to record daily  if any elective procedures have been performed, signs and 
symptoms of angioedema attacks, triggers for angioedema attack s, medications used for the 
management of angioedema attacks, and interruptions in activities of daily  living due to an 
angioedema attack.  Section (a) is to be completed by  [CONTACT_7071]/caregiver ,and when possible, 
the same parent/caregiver should be respo nsible for completing this section of the eDiary 
throughout the stud y.
(b) Section to record the impact of HAE on quality  of life (EQ-5D- Y).  Section (b)is to be 
completed by [CONTACT_70543] .  
Study  personnel will contact [CONTACT_7071]/caregiver by [CONTACT_70544]- weekly (Weeks 2, 4, 6, 8, 
10, and 12) during the baseline observation period to discuss study  compliance (completion of
theeDiarydaily )and to evaluate the subject’s angioedema attack frequency ( Schedule 1).
During the baseline observation period, subjects are allowed to remain on any prophylactic 
HAE 
therap y they were receiving prior to study  enrollment , if clinically  indicated .  However, 
it is recommended that consideration by [CONTACT_70545] [ADDRESS_76849] discontinue this therapy .  
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 20 CONFIDENTIALIn the event that during the 12 weeks of baseline observation subjects do not meet the attack 
criteria qualify ing for randomization (≥1.0 angioedema attacks per month [average] that are 
moderate or severe or require acute treatment ), despi[INVESTIGATOR_70522], additional weeks of observation will be considered at the 
discretion of the Investigator and Sponsor to allow qualification for randomization and entry  
into the treatment periods of the study .  In this case, subject s will maintain the same schedule 
of assessments by [CONTACT_70546] 1 again for the additional weeks of observation 
(Schedule 1).
After the completion of the baseline observation period, s ubjects who remain eligible per 
study criteria will be randomized to one of two treatment sequences, with each sequence 
consisting of two treatment periods.  In Treatment Period 1, subjects will receive CINRYZE 
at a dose of either 500 U or 1000 U IV twice weekly  (every  3 or 4 day s), dependi ng upon their 
randomized assignment.  After completion of the first treatment period, subjects will 
immediately  crossover to the alternate CINRYZE dose and begin Treatment Period 2.
This is a single -blind study .  Subjects and parents/caregivers will be blinded to the treatment 
administered.  Study site personnel, home health care professionals, and the Sponsor will not 
be blinded to dose and treatment sequence.  Study  drug will be administered intravenously  by 
[CONTACT_70547], or by  [CONTACT_70548]’s home or other agreed upon location.  Alternatively  if allowed per local 
regulations, subjects who have been trained to self-administer C1INH or who have a non-
healthcare provider (e.g. parent
) who has been trained to administer C1 INHwill be permitted 
to do sobased upon the request of the subject (and with approval of the parent(s)/legal 
guardian and the Investigator ).  Note: self-administration will always occur under the 
supervision of a qualified healthcare professional at the study  site or the subject’s home (or 
other agreed upon location). Supervision by a qualified healthcare professional will include 
real time direct visual observation of the following: selection of the injection site, preparation 
of the injection site, insertion of the infusion device into the vein, study  drug infusion, 
removal of infusion device, compression and apply ing a bandage to the injection site, and 
disposal of all infusion materials.
The Investigator or designee will monitor and document study  compliance, tolerability  of 
each CINRYZE dose, and adverse events.  The following doses of study  drug in each 
treatment period must be administered at the investigational site:  Dose 1 (Visits 1a and 1b, 
where a=treatme nt period 1 and b=treatment period 2), Dose 12 (Visits 12a and 12b) and 
Dose 24 (Visits 24a and 24b).  At these visits, subjects will also have other scheduled 
procedures performed (Schedules 2and 3).  For those subjects who are administered study  
drug at a location other than the study  site, study personnel will contact [CONTACT_7071]/caregiver
by [CONTACT_70538] (Week 3 after Dose 6 [Visits 6a and 6b] and 
Week 9 after Dose 18 [Visits 18a and 18b]) .  If study  drug is administered at the site (Doses 6 
and 18), no telephone contact [CONTACT_70549] .
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 21 CONFIDENTIALTo the extent possible, subjects will postpone elective procedures (e.g., dental work) while 
participating in the study .  In the event a procedure cannot be postponed, parents /caregivers 
will notify  the Investigator and the information will be record edin the subject’s eCRF .
A post-treatment visit will be performed at the investigative site 1 week (±2 days) after the 
last dose of study  drug for follow -up safet y assessments.  In addition, subjects will have a 
blood sample for C1INH antibody  testing collected 30 (±2) days after the last dose of study  
drug.  If a subject discontinues prematurel y from treatment and/or the study , the Investigator 
will perform the early discontinuation visit safety  procedures as soon as possible
(Schedule 4).  For those subjects who discontinue prematurely  from treatment, every  effort 
should be made to complete protocol evaluations for the1-month post-treatment follow -up 
visit. 
The schedules of study  procedures are provided immediately  following the sy nopsis:
Schedule 1:   Clinical study  assessments – Screening and Baseline Observation 
Period (Weeks 1 to 12).
Schedule 
2:  Clinical study  assessments –Trea tment Period 1 (Visits 1a to 24a).
Schedule 3:   Clinical study  assessments – Treatment Period 2 (Visits 1b to 24b).
Schedule 4: Clinical study  assessments – Early Discontinuation, 1-week P ost-
treatment, and [ADDRESS_76850]-treatment 
Follow -up V isits.
Schedul e 5:  Blood sample collection –PK/PD and post -treatment 
immunogenicit y assessments.
Definition of an Angioedema Attack
An angioedema attack will be defined as any subject -reported (or parent/caregiver -reported) 
indication of swelling or pain at any locati on following a report of no swelling or pain on the 
previous day(i.e., there must be a full symptom -free calendar day preceding the onset of 
symptoms for an attack to be considered a new attack).  Therefore, 
Attacks that progress from one site to another will be considered a single attack, 
Attacks that begin to regress and then worsen before complete resolution will be 
considered one attack, and
Attacks that begin, appear to resolve, and then reappear without a s ymptom -free 
calendar day  reported after th e appearance of resolution will also be considered 
one attack.
NOTE:   An angioedema attack does NOT include swelling due to trauma or symmetrical 
non-painful swelling of the lower extremities.
Management of Angioedema Attacks
If a subject experiences an angioedema attack that in the opi[INVESTIGATOR_70523], the choice of acute treatment will be left to the Investigator’s 
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76851] adhering 
to the study schedule , regardless of whether C1INH therapy or other products were 
administered to treat the attack.   
NOTE:  If a subject presents to the site with an angioedema attack, every  effort should be 
made to obtain a PK blood sample prior to any  treatment.  In addition, if the subject is treated 
with commercial C1INH, every effort should be made to obtain a 1-hour post-treatment 
sample.
  These samples will be anal yzed for C1 INH antigen and functional C1 INH activit y.
To the extent possible during the study , subjects should avoid any stimuli (e.g., foods, 
activities, environ ments) known to trigger their angioedema attacks.  Otherwise, subjects may 
maintain their normal diets, medications, and activities of daily  living.
Safety  Monitoring
Safety  will be monitored through the recording of adverse events (AEs) and any changes in
medical history , physical examinations, vital signs, and clinical safet y laboratory  testing 
(hematology , chemistry , and coagulation).  Testing of blood samples for clinical laboratory  
parameters will be p erformed at a Central Laboratory .
Investigators will report all serious adverse events (SAEs) occurring up to [ADDRESS_76852]-treatment (or if prematurely  discontinued), and at the 1-month 
post-treatment follow -up visit to monitor for C1 INH antibodies (see Schedules 2, 3, 4, and5).
Pharmacokinetics and Pharmacod ynamics
Blood samples for PK (functional and antigenic C1 INH) and PD (complement C4) 
assessments will be collected at pre-specified time points in both treatment periods (see 
Schedule 5).
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 23 CONFIDENTIALQuality  of Life Measurements
EQ-5D-Y1(Youth version of EQ-5D) is a descriptive system of youth health -related quality 
of life states consisting of five dimensions each of which can have one of three responses.  
The responses record the level of severit y within a particular EQ-5D dimension.  EQ-5D- Y is 
not intended for use in children 6 years of age; however in this study  all subjects (6 to 11 
years of age and where translated language version is available) will beassessed.  The 
EQ-5D-Y will be completed by [CONTACT_70550] 1, 2, 3, 
and [ADDRESS_76853] experiences signs or symptoms of an angioedema
attack.
Statistical Considerations:  
Sample Size :  Twelve subjects will be randomized in this study .  Subjects will be randomized 
to one of two treatment sequences so that upon completion of the study , each subject will 
have received both dose levels of CINRYZE (500 U and 1000 U).Based on the EU Pediatric 
Investigation Plan, anadministrative look for regulator y purpose may be completed after [ADDRESS_76854] finished the study .  A final CSR will be completed after 12 subjects finish the 
study .  
Primary  efficacy  endpoint :  The primary  efficacy  endpoint is the number of angioedema 
attacks normalized to a 12-week treatment period .  This endpoint will be measured for each 
subject in each trea tment period.  
Secondary  efficacy  endpoints:
The following will be measured for each subject in each treatment period:
Cumulative Attack Severity .  This score is the sum of the maximum symptom 
severit y recorded for each angioedema attack in a treatment pe riod.  
Cumulative Daily  Severity .  This score is the sum of the severity  scores recorded 
for every  day of reported sy mptoms in a treatment period.  
Time (measured in days from the first dose of study  drug in a treatment period) to 
the first angioedema at tack reported in that treatment period.
Change from pre-to post -dose in C1 INH functional activity , C1 INH antigen, and 
C4 levels.
Number of angioedema attacks requiring acute treatment during each treatment 
period.
Analy sis of efficacy  endpoints will employ  descriptive statistics and will include all subjects 
randomized and treated with study  drug.
If warranted by [CONTACT_26739], the comparison of CINRYZE doses will employ  a paired t-test to 
perform a two-sided test of superiorit y (1000 U vs. 500 U) conducted at α=0.10.  
                                                
1EQ-5D™ is a trade mark of the EuroQol Group.
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 24 CONFIDENTIALSafety  Endpoints:
The following will be assessed during the study :
Safety  and tolerability , including:
adverse events b y dose group
adverse events b y exposure (dose normalized to body weight [U/kg])
adverse events by [CONTACT_70551] (e.g., during administration of study  drug 
or within 24 hours after the end of injection of study  drug) 
Summary  statistics and changes from baseline to post-baseline for safet y 
laboratory  testing and vital signs by  [CONTACT_7169].
Results of C1 INH antibody  testing will be reported for individual subjects and 
summarized as appropriate. 
PK/PD Endpoints:
Concentrations of C1 INH antigen, functional C1 INH activity , and complement C4 
for individual subjects will be determined using validated analytical methods.  Results 
will be summarized using descriptive statistics for values at each time point and for 
change from baseline at each post -injection time.
Other Endpoints:
Results of the EQ-5D-Y health status questionnaire will be presented in 
accordance with the EQ-5D- 3L UserGuide (version 4.01), and adapted as 
appropriate for the youth version
.
                                                
1EQ-5D-3L User Guide: Basic information on how to use the EQ-5D-3L questionnaire .  Version 4.0, April 
2011.  Published by [CONTACT_70552].
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 25 CONFI DENTIALSCHEDULE 1: CLINICAL STUDY ASSESSMENTS –SCREENING AND BASELI NE OBSERVATION 
PERIOD
Procedures Screening aBASELINE OBSERVATION PERIOD (BY [CONTACT_70553])b
1 2 3 4 5 6 7 8 9 10 11 12
Informed consent (written 
permission and assent)X
Medical/ HAE history X
Prior/current medicationscX X ------------------------------------------------------------------------------------------------------------------------- -------------------- X
Telephone contact[CONTACT_70554] X X X X X
Daily a ngioedema attack 
monitoring/ eDiarye X----------------------- ---------------------------------------------------------------------------------------------------------------------- X
EQ-5D-Y/eDiaryfX X X
eDiary=electronic study diary; EQ-5D-Y (Youth version of EQ -5D)=health -related quality of life descriptive system for youth
a: All subjects will have a screening evaluation the day prior to entering Week 1 of the baseline obs ervation period .  
b: Additional weeks of observations will be considered at the discretion of the Investigator and Sponsor to allow a subject to qualify for randomization and entry into the 
treatment periods of the study.   In this case, s ubjects will main tain the same schedule of assessments by [CONTACT_70546] 1 again for the additional weeks of observation
(i.e.,Week 13=
schedule of assessments for Week 1, Week 14 = schedule of assessments for Week 2, etc).
c: Parent s/caregivers should record in the eDiary any medications taken by [CONTACT_70555].
d: Study personnel will contact [CONTACT_7071]/caregiver by [CONTACT_70556] 2,4, 6, 8, 10, and 12 to discuss study compliance (comp letion of the eDiary daily )and to evaluate
the subject’s angioedema attack frequency .  Telephone contacts will be documented in the source notes at the clinical site.
e: During the baseline observation period , parents /caregivers will use a n eDiary to reco rd the subject’s 
symptoms or occurrences of angioedema attacks.
f: In addition, subjects should complete the EQ -5D-Y on each day that they experience signs or sym ptoms of an angioedema attack.
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 26 CONFI DENTIALSCHEDULE 2: CLINICAL STUDY ASSESSMENTS – TREATMENT PERIOD 1
ProceduresTREATMENT PERIOD 1 (BY [CONTACT_70553]) a
1 2 3 4 5 6 7 8 9 10 11 12
DOSING VISITS (1a to 24a)
1a 2a 3a 4a 5a 6a 7a 8a 9a 10a 11a 12a 13a 14a 15a 16a 17a 18a 19a 20a 21a 22a 23a 24a
Confirm eligibility Xb
Randomization Xc
Medical history update /Physical 
exam d XbX X
Concomitant medications X X X X X X X X X X X X X X X X X X X X X X X X
Height and Body Weight Xb
Vital signs (BP, HR) eXfX X X X X X X X X X X
Clinical safety lab testing. 
(hematology, chemistry, 
coagulation)X bX
Virology screening gX b
Pregnancy testinghX b
Study drug administration XiX X X X X X X X X X X iX X X X X X X X X X X X i
Telephone contact [CONTACT_70557] X
EQ-5D-Y/eDiarykX bX X
Daily a ngioedema attack 
monitoring /eDiaryX-------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ---------- X
Adverse events X------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------- X
PK/PD assessments Details on timing of blood sample collection for PK/PD assessments is provided in Schedule 5.
Immunogenicity testing (C1 INH 
antibody)X.b
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 27 CONFI DENTIALeDiary=electronic study diary; EQ-5D-Y (Youth version of EQ -5D)=health -related quality of life descriptive system for youth
a: Study drug administration and scheduled procedures will occur twice weekly (every 3 or 4 days) during th e 12-week treatment period (Treatment Period 1, Visits 1a- 24a).
b: Specified study procedures and blood samples should be performed/collected prior to study drug administration , on the same day .  
c: Randomization will occur on Dosing Day 1 (Visit 1a) prio r to the first dose of study drug in Treatment Period 1.
d: Medical history will be updated prior to randomization at Visit 1a.  Physical examinations will be targeted based on reportin g of adverse events and performed in accordance with standards at the s ite.
e: Vital signs will be measured using standard methods at each study site.  On dosing days, vital signs should be obtained prior (within 60 minutes) to the injection of study drug and between 10 to 30 
minutes after completion of the injection of study drug.  Additional vital signs measurements may be performed if clinically indicated.
f: Body temperature should be measured prior to randomization at Visit 1a .
g: HIV (single assay antibody/Western Blot) and hepatitis (Hepatitis B Surface Antigen, Hepati tis C Antibody).
h: Pregnancy testing (urine) will be performed on females who have reached menarche. 
i: Study drug will be administered by /under supervision of qualified personnel to all subjects at the investigational site for Dosing Visits 1a, 12a, and 24a.
j: For those subjects who are administered study drug at a location other than the study site ,study personnel will contact [CONTACT_7071]/caregiver by[CONTACT_70556] 3 and 9 (after Dosing Visits 6a and 
18a, respectively )to discuss and document stud y compliance, tolerability of CI NRYZE dose, and adverse events.  All telephone contacts will be documented in the source note s at the clinical site.
k: In addition, subjects should complete the EQ -5D-Y on each day that they experience signs or symptoms of an angioedema attack .
See Schedule 4 for details regarding clinical assessments at early discontinuation (if applicable), [ADDRESS_76855] prematurely discontinues from treatment and/or the study, Early Discontinuation Visit procedures will be performed as soon as possible.
NOTE:   Investigators will report all SAEs to Shire VIROPHARMA Drug Safety through [ADDRESS_76856] dose of study drug and SAEs considered related to study drug >[ADDRESS_76857] dose of study 
drug.
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 28 CONFI DENTIALSCHEDULE 3: CLINICAL STUDY ASSESSMENTS – TREATMENT PERIOD 2
ProceduresTREATMENT PERIOD 2 (BY [CONTACT_70553]) a
1 2 3 4 5 6 7 8 9 10 11 12
DOSING VISITS (1b to 24b)
1b 2b 3b 4b 5b 6b 7b 8b 9b 10b 11b 12b 13b 14b 15b 16b 17b 18b 19b 20b 21b 22b 23b 24b
Physical exam b  X dX X
Body Weight   X d
Concomitant medications X X X X X X X X X X X X X X X X X X X X X X X X
Vital signs (BP, HR) cX X X X X X X X X X X X
Clinical safety lab testing. 
(hematology, chemistry, 
coagulation)  X dX X
Study drug administration   X eX X X X X X X X X X X eX X X X X X X X X X X X e
Telephone contact [CONTACT_70558] X
EQ-5D-Y/eDiaryg, h  X dX X
Daily a ngioedema attack 
monitoring/ eDiaryh X----------------------------------------------------------------------------------------------------------------------------- ------------------------------------------- --------------------------- X
Adverse events X----------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- X
PK/PD assess ments Details on timing of blood sample collection for PK/PD assessments is provided in Schedule 5.
Immunog enicity testing 
(C1INH antibody )  X d
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 29 CONFI DENTIALeDiary=electronic study diary; EQ-5D-Y (Youth version of EQ -5D)=health -related quali ty of life descriptive system for youth
a: Study drug administration and scheduled procedures will occur twice weekly (every 3 or 4 days) during the 12- week treatment period (Treatment Period 2, Visits 1b -24b).  
b: Physical examinations will be targeted b ased on reporting of adverse events and performed in accordance with standards at the site.
c: Vital signs will be measured using standard methods at each study site.  On dosing days, vital signs should be obtained prior (within 60 minutes) to the injectio n of study drug and 
between 10 to 30 minutes after completion of the injection of study drug.  Additional vital signs measurements may be perform ed if clinically indicated.
d: Specified study procedures and blood samples should be performed/collected prior to study drug administration , on the same day .  
e: Study drug will be administered by /under supervision of qualified personnel to all subjects at the investigational site for Dosing Visits 1b, 12b, and 24b .
f: For those subjects who are administered stud y drug at a location other than the study site , study personnel will contact [CONTACT_7071]/caregiver by [CONTACT_70556] 3 and 9 (after Dosing 
Visits 6b and 18b , respectively )to discuss and document study compliance, tolerability of CINRYZE dose, and adver se events.  All telephone contacts will be documented in the source 
notes at the clinical site.
g: In addition, subjects should complete the EQ -5D-Y on each day that they experience signs or symptoms of an angioedema attack .
h: If an angioedema attack is o ngoing at Visit 24b, then recording of signs and symptoms and completing the EQ -5D-Y should continue daily until the attack resolves. 
See Schedule 4 for details regarding c linical assessments at early discontinuation (if applicable), [ADDRESS_76858] prematurely discontinues from treatment and/or the study, Early Discontinuation Visit procedures will be performed as soon as possible.
NOTE:   Investigators will report all SAEs to Shire VIROPHARMA Drug Safety through [ADDRESS_76859] dose of study drug and SAEs considered related to study drug >[ADDRESS_76860] dose of study drug.
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 30 CONFIDENTIALSCHEDULE 4: CLINICAL STUDY ASSESSMENTS – EARLY 
DISCONTINUATION, [ADDRESS_76861]-treatm ent
Follow -up Visit c
Concomitant medications X X
Brief physical examination dX X
Vital signs (BP, HR) eX X
Clinica l safety lab testing (hematology, 
chemistry, coagulation)X X
Pregnancy testingfX X
EQ-5D-Y X X
Adverse events X X
Immunogenicity testing (C1 INH antibod y) X X X
Virology testing gX X
EQ-5D-Y (Youth version of EQ-5D)=health -related quality of life descriptive system for youth
a: Early discontinuation visit will be performed as soon as possible in the event a subject prematurely discontinues 
from treatment and/or the study.  For those subjects who discontinue prematurely from treatment, every effort 
should be made to complete protocol evaluations for the [ADDRESS_76862] -treatment follow -up visit. 
b: 1-Week p ost-treatment visit will be performed at the investigational site 1 week (±2 days) after the last dose of 
study drug.
c: 1-Month post-treatm ent follow -up visit will be performed 30 (±2) days after the last dose of study drug.  
d: Physical examinations will be targeted based on reporting of adverse events and performed in accordance with 
standards at the site.
e: Vital signs will be measured using standard methods at each investigational site.  
f: Pregnancy testing (urine ) will be performed on females who have reached menarche. 
g: HIV (single assay antibody/Western Blot) and hepatitis (Hepatitis B Surface Antigen, Hepatitis C Antibody).
NOTE :  Investigators will report all SAEs to Shire VIROPHARMA Drug Safety through [ADDRESS_76863] dose of 
study drug and SAEs considered related to study drug >[ADDRESS_76864] dose of study drug.
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 31 CONFIDENTIALSCHEDULE 5: BLOOD SAMPLE C OLLECTION FOR PK /PDAND 
POST -TREATMENT IMMUNOGENI CITY 
ASSESSMENTS
TREATMENT PERIOD 1
Visit / Dose #Blood Sam pling Time Points
C1 INH Antigen, C1 INH Function , Complement C4
1a / Dose [ADDRESS_76865] Dose 1 (± 15 min)
12a/ Dose [ADDRESS_76866] Dose 1 2(±15 min)
24a / Dose [ADDRESS_76867] Dose 24 (± 15 min)
[ADDRESS_76868] Dose 24 (± 15 min) –optional sampling time point
[ADDRESS_76869] Dose 24 (± 15 min) –optional sampling time point
[ADDRESS_76870] Dose 24 (± 15 min) –optional sampling time point
TREA TMENT PERIOD 2
Visit / Dose #Blood Sam pling Time Points
C1 INH Antigen, C1 INH Function , Complement C4
1b / Dose [ADDRESS_76871] Dose 1 (± 15 min)
12b/ Dose [ADDRESS_76872] Dose 1 2(± 15 min)
24b / Dose 24 Pre Dose 24 
1 h pos t Dose 24 (± 15 min)
[ADDRESS_76873] Dose 24 (± 15 min) –optional sampling time point
[ADDRESS_76874] Dose 24 (± 15 min) –optional sampling time point
[ADDRESS_76875] Dose 24 (± 15 min) –optional sampling time point
NOTE:   If a subject presents to the investigational site with an angioedema attack, every effort should be made 
to obtain a PK blood sample prior to any treatment .  In addition, if the subject is treated with commercial
C1INH, every effort should be made to obtain a [ADDRESS_76876] -TREATMENT
Visit Blood Sam pling Time Points
Immunogenicity (C1 INH antibod y)
1-week post -treatment 1 week (± 2 days) after the last dose of study drug
1-month post -treatmen t 30 (± 2) days after the last dose of study drug
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 32 CONFIDENTIAL1.0 INTRODUCTION
Hereditary  angioedema (HAE) is an autosomal dominant disease resulting from mutations of 
the C1 inhibitor (C1 INH) gene and deficient plasma C1 INH protein.  Nearly all affected 
individua ls experience symptoms of the disease; however, the symptoms vary in both their 
frequency  and severity  (Gompels et al., 2005; Zuraw, 2003 ).  The diagnosis of a C1INH 
deficiency  is suggested by a history  that includes recurrent attacks of angioedema, 
characterized by [CONTACT_105]-itching swelling of the skin or mucosa.  Serum C4 ,C1INH antigen ,and 
functional C1 INH levels can be measured 
to assist with the diagnosis of HAE.  A low level 
of C4 in combi nation with a low level of either C1 INH antigen (Type I HAE) or functional 
C1 INH (Type II HAE) are confirmatory  for the diagnosis of HAE (Frank et al., 1976).  In 
rare instances, C4 levels may be normal in HAE patients between attacks, but are almost 
alway s decreased during epi[INVESTIGATOR_70524] ( Frank et al., 1976).  In this circumstance, 
a low serum C4 level during an epi[INVESTIGATOR_70525] H AE ( Frank et al., 1976 ; Way tes et al., 1996). 
Attacks of HAE are usually  self-limiting, but can be quite painful, disfiguring, disabling, and 
sometimes fatal.  Edema can involve the skin and visceral organs, but most frequentl y 
manifests in the extremities or bowel; the swelling generall y lasts 2 to 5 days (Nzeako et al., 
2001; Zuraw, 2008).  Abdominal attacks have been reporte d to occur in >93% of patients and 
account for nearl y 50% of all angioedema attacks (Zuraw, 2008).  Not infrequentl y, an 
abdominal HAE attack can imitate a surgical emergency .  Life-threatening laryngeal edema 
may also occu r and this accounts for the majorit y of the 30% to 40% mortality  rate reported 
for this disease ( Agostoni and Cicardi, 1992; Bork et al., 2000 ).
Intravenous administration of C1INH, the plasm
a protein that is deficient in patients with 
HAE, has been used in Europe for more than 30 years for the treatment of acute attacks of 
HAE (Wall and Frank, 1990; Gadek et al., 1980 ).  C1 INH concentrates are prepared from 
pooled human plasma.  The efficacy  of purified C1 I NH concentrates in the treatment of acute 
angioedema in HAE has previously  been described (Agostoni et al., 1980;  Bergamaschini et 
al., 1983 ; Logan and Greaves, 1984 ; Späth et al., 1984
).  
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 33 CONFIDENTIALThe median age at the onset of initial symptoms is reported tobetween 8 and 12 years ;
however HAE can occur inthe first year of life(Farkas et al., 2007 ; Farkas et al., 2002) .  A 
large -scale study  conducted by [CONTACT_70559]. (2006) showed that the yearly number of attack s is 
approximately  double in patients when the disease appeared before age [ADDRESS_76877] in 
children 6 to 11 years of age who require long-term C1 INH replacement therap y due to the 
morbidity  imposed by  [CONTACT_70560].  
1.1 C INRYZE® (C1 esterase inhibitor [human])
CINRYZE®(C1 esterase inhibito r [human ]) consists of a protein fraction prepared from 
human plasma.  The manufacturing process includes 3 virus inactivation/removal steps: 
polyethylene glycol precipi[INVESTIGATOR_332], pasteurization, and nanofiltration.  CINRYZE is a normal 
human plasma protein that is not subject to Cytochrome P450 metabolism, excretion, or 
pharmacokinetic (PK) drug- drug interactions exhibited by  [CONTACT_70561].  
CINRYZE was approved by  [CONTACT_24623] ( US)Food and Drug Administration (FDA) for 
routine proph ylaxis against angioedema attacks in adolescent and adult patients with HAE in 
October 2008.  CINRYZE was approved throughout the European Union (EU), via the 
Centralized Procedure, in June 2011 for treatment and pre-procedure prevention of 
angioedema attacks in adults and adolescents with HAE, and routine prevention of 
angioedema attacks in adults and adolescents with severe and recurrent attacks of HAE who 
are intolerant to or insufficiently  protected by [CONTACT_70562], or patients who are 
inade quatel y managed with repeated acute treatment.   CINRYZE has also received marketing 
authorization in Australia (2012), Canada (2012), India (2013) ,Switzerland (2013) , and Israel 
(2013) .
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 34 CONFIDENTIAL1.1.1 Nonclinical Experience with Intravenous Administration
Acute and repeated-dose toxicity  studies were performed in rats with IVadministration of 
CINRYZE at dose levels of 20, 100 ,and 400units(U)/kg/day .  The highest dose evaluated in 
animals without observable adverse effects (400 U/kg) represents a safet y margin of 
approximately  10 to 28 times the recommended human dose for adults and pediatrics (1000 U 
in adults, adolescents, and children 6 years of age and above).  In the repeated -dose study , the 
signs of toxicity  were limited to minor increases in inflammatory  changes in the lungs and 
germinal center hypertrophy  in the spleens of animals dosed at 400U/kg/day  for 14days, as 
compared to control animals.  The amount of germinal center hypertrophy  in the spleens of 
rats treated at 400U/kg/day  was within the normal backg round histopathological range in 
both incidence and severity , but did correlate with a small increase in splenic weights, which 
may have been a reflection of the inflammatory increase in the lungs.  Since CINRYZE is 
derived from human plasma, an immunologi cal effect in rats is to be expected. 
Results of an exvivo thrombogenicit y study  utilizing health y human volunteer whole blood 
and platelet poor plasma showed no evidence of a hypercoagulable effect of CINRYZE at 
concentrations of 0.14- 7.0U/mL  (approxim ately 7times physiologic concentration).  These 
findings were consistent with a toxicology  study of CINRYZE in rats, where no signs of 
thrombogenicit y were observed at doses up to 400 U/kg/day for 14 days.  
No effects of C1INH on embry o
-fetal developmen t were observed at dose levels up to 
400U/kg.  No animal studies have been completed to evaluate the effects of CINRYZE on 
carcinogenesis, mutagenesis, or impairment of fertility .
1.1.2 Clinical Experience with Intravenous Administration
The HAE development program for IV CINRYZE in the US included 2 multicenter studies of 
CINRYZE for prevention of angioedema attacks (1 double -blind, placebo -controlled study ; 1 
open -label study ) and 2 multicenter studies of CINRYZE for treatment of angioedema attacks 
(1 double -blind, placebo -controlled study ; 1 open -label study ).  In the double -blind prevention 
study (LEVP 2005- 1/B), CINRYZE was shown to reduce the incidence of HAE attacks in 22 
subjects anal yzed (mean normalized 12 -week HAE attack rate:  6.3 for CINRYZE vs. 12.7 for 
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 35 CONFIDENTIALplacebo1; p<0.0001) .  In the double -blind treatment study (LEVP 2005 -1/A), subjects 
receiving CINRYZE achieved beginning of unequivocal relief of the defining HAE symptom 
at a rate 2 times greater than subjects receiving placebo (p=0.017 for the Effic acy Dataset of 
68 subjects [35 CINRYZE , 33placebo]).
More than 14,[ADDRESS_76878] 
majority  of infusions were CINRY ZEdoses of 1000 U.  In the clinical studies ,local reactions 
(e.g., pain, bruising, or rash at the injection/catheter site, venous burning or phlebitis) 
occurred in association with approximately  0.2% of infusions.  No subjects were discontinued 
from CINRYZE due to an adverse 
event (AE)in any CINRYZE study  completed to date
evaluating the IV formulation .  No serious adverse events (SAEs) were considered by [CONTACT_70563], probabl y, or definitely related to treatment with CI NRYZE.
Thrombot ic and thromboembolic (T/TE) events have been reported following administration 
of IV C INRYZE 1000 U every  3 or 4 day s as well as with higher than the recommended dose.  
Five subjects in the completed studies of the HAE development program for IV CINRYZE 
experienced SAEs that were thrombotic or thromboembolic in nature. The majorit y (4/5, 
80%) of these events occurred in subjects with thrombogenic risk factors and none of these 
events were considered by [CONTACT_70564].  
In a post-approval open -label study  (0624- 400) there were no systemic thrombotic events in 
subjects (n=20) who received IV CINRYZE up to [ADDRESS_76879] developed a blood clot in an intravenous central catheter, which was 
treated locally  without systemic complication.  Nevertheless, patients with known risk factors 
for thrombotic events (including indwelling catheters) should be monitored closely.  
Evaluation of the clinical PK and pharmacod ynamics (PD) following IV admini stration of 
CINRYZE in 
subjects with HAE was primarily  based on the results of Protocol 
LEVP 2006- 5.  After IV administration of CINRYZE 1000 U, functional C1INH
                                                
1Mean observed 12-week HAE attack rate:  6.1 for CINRYZE vs. 12.7 for placebo per CINRYZE US 
Package Insert (2012).
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 36 CONFIDENTIALconcentrations increased from a mean baseline value of 0.31 U/mL to a maximum 
concentration (Cmax) of 0.68 U/mL .  Two consecutive 1000 U doses administered 60 minutes 
apart produced a mean C max of 0.85 U/mL .  Median time to maximum concentration (t max) was 
approximately 1to 2 hours.  The mean terminal elimination half-life (t1/2) of functional C1
INH was approximately 60 hours using noncompartmental methods.  Mean clearance (CL) 
values for functional C1INH were 0.85 and1.17 mL/min for the single and double doses , 
respectivel y.  Mean Cmaxvalues for C1INH antigen following IV administration of 
CINRYZE were 1.48 and 1.70 U/mL  for the single and double doses, respectively .  Median 
tmaxwas approximately  1.5 hours.  The mean t1/2of antigenic C1INH was approximately  45 
to 47 hours and mean CL was 0.70 mL /min.
1.1.3 Pediatric Experience with Intravenous A dministration
In the 2multicenter studies of CINRYZE for prevention of angioedema attacks and 2 
multicenter studies of CINRYZE for treatment of angioedema attacks, 46 unique pediatric 
subjects (aged 2-17 years) received a total of 2,237 infusions of IV CINRYZE (see Table1; 
Lumry  et al., 2013) .  There were 19unique subjects 6-[ADDRESS_76880] majority  of infusions used CINRY ZEdoses of 
1000 U.  While the pediatric subsets in various studies had few subjects, analyses of efficacy  
by [CONTACT_70565] (as either HAE treatment or prevention) 
was generall y comparable between children and adults.  
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 37 CONFIDENTIALTable1. Number of P ediatric Subjects Exposed to CINRYZE and Total 
Infusions by  [CONTACT_70566], Indication, and Study – ITT-S Population
Indication
Study a2-5 years
Number of Subjects
(number of infusions)6-11 years
Number of Subjects
(number of infusions)12-17 years
Number of Subjects
(number of infusions)
Treatm ent
LEVP 2005 -1/A 0 6 (19) 6 (11)
LEVP 2006 -1 1 (2) 10 (116) 13 (75)
Prevention
LEVP 2005 -1/B 0 1 (93) 3 (126)
LEVP 2006 -4 2 (47) 9 (828) 12 (920)
Total b3 (49) 26 (1,056) 34 (1,132)
a:Subjects may have been exposed to CINRYZE in one or more studies.
b:A subject may be counted more than once in the total if the subject participated in more than one study; 
therefore, this number represents the total number of subject exposures within each age subset.
CINRYZE had a favorable safety  profile ,with no clinically  meaningful adverse trends 
observed among pediatric subjects.  An overall summary from the [ADDRESS_76881] sthatwere considered by [CONTACT_70567] 2.  
Table 2. Incidence of Treatment -Emergent A dverse Events Related to 
Study Drug Among Pediatric Subjects Exposed to CINRYZE by 
[CONTACT_70566], Indic ation, and Study  –ITT-S Population
Indication
Study a2-5 years 6-11 years 12-17 years
n/N (%)
Treatm ent
LEVP 2005 -1/A --- 0/6 (0%) 0/6 (0%)
LEVP 2006 -1 0/1 (0%) 0/10 (0%) 0/13 (0%)
Prevention
LEVP 2005 -1/B --- 1/1 (100%) 0/3 (0%)
LEVP 2006 -4 0/2 (0%) 2/9 (22%) 2/12 (17%)
Total, n/N b0/3 (0%) 3/26 (12%) 2/34 (6%)
n/N=number of subjects w ith ≥1 treatment -related AE/number of subjects in a given age group by [CONTACT_3449]
a:  Subjects may have been exposed to CINRYZE in one or more studies.
b:  n/N=number of subjects with ≥1 treatment -related AE across studies (a given subje ct may be counted 
more than once in the total if the subject participated and had a treatment -related AE in more than one 
study)/total number of subject exposures within each age subset.
CI N R Y Z E ® ( C 1 esterase i n hi bit or [h u ma n] )
Pr ot oc ol [ADDRESS_76882] u g a n d t he e ve nts 
are descri be d bel o w :
St u d y  L E V P 2 0 0 5- 1/ B: O ne c hil d years of a ge), e x perie nce d m o derate p y re xia 
deter mi ne d b y  t he I n vesti gat or t o be p ossi bl y relate d t o st u d y  d r u g; t he e ve nt res ol ve d 
after a d urati o n of 1 da y .
St u d y  L E V P 2 0 0 6- 4:  F o ur c hil dre n re p orte d ≥ 1 treat me nt -relate d A E, as detaile d bel o w: 
6- 1 1 years of a ge:  2 / 9 ( 2 2 %) s u bjects re p orte d 4 relate d treat me nt -e mer ge nt A Es 
( dizzi ness, hea dac he, m o ut h ulcerati o n, a n d na usea) 
1 2- 1 7 ye ars of a ge:  2 / 1 2 ( 1 7 %) s u bjects re p orte d 3 relate d treat me nt - e mer ge nt 
A Es (i nf usi o n site er y t he ma, metr orr ha gia, a n d p h ot ose nsiti vit y  reacti o n) 
Of n ote, se veral of t hese e ve nts are i ncl u de d a m o n g t he rel ate d treat me nt -e mer ge nt A Es o nl y 
beca use t he I n vesti gat or c o nsi dere d t he m t o be of “ u n k n o w n” relati o ns hi p t o CI N R Y Z E 
( dizzi ness, m o ut h ulcerati o n, metr orr ha gia, a n d p h ot ose nsiti vit y  r eacti o n).  T he o nl y e ve nts 
c o nsi dere d b y  t he I n vesti gat or t o be p ossi bl y , pr o ba bl y , or defi nitel y relate d t o CI N R Y Z E 
were hea dac he, na usea, a n d i nf usi o n site er y t he ma , all of w hic h were mil d i n se verit y  a n d 
res ol ve d after a d urati o n of [ADDRESS_76883] u dy L E V P 2 0 0 5 -1/ B 
P P D I n t he pi v otal st u d y  o f CI N R Y Z E f or t he pr e ve nti o n of H A E attac ks ( Pr ot oc ol 
L E V P 2 0 0 5 -1/ B), 4 pe diatric s u bjects were e nr olle d (ra n ge: ye ars; me dia n: 1 5 ye ars ), 
eac h of w h o m ha d pre vi o usl y  p artici pate d i n St u d y  L E V P 2 0 0 5 -1/ A.  S u bjects were 
ra n d o mize d i n a 1: 1 rati o t o o ne of t w o pre ve nti o n t hera p y se q ue nces:  [ADDRESS_76884] u d y t o be c o nsi dere d a n “ o n -de ma n d” c o m parat or.  P P D 
CI N R Y Z E ® ( C 1 esterase i n hi bit or [h u ma n] )
Pr ot oc ol [ADDRESS_76885] b o/ o n -de ma n d 
t hera p y( mea n n u m ber of attac ks pe r peri o d:  7. 0 vs. 1 3. 0).  
T a bl e 3.S u m m ar y  of Effi c a c y  R e s ult s f or P e di atri c S u bj e ct s ( N = 4) –
St u d y L E V P 2 0 0 5 -1/ B                                        
Me a n O bser ve d N o. of 
Att ac ks D uri n g 
T her a p y Me a n Se verit y a
of Att ac ks D uri n g 
T her a p y Me a n D ur ati o n 
of Att ac ks D uri n g 
T her a p y ( D a ys) Me a n N o. of O L 
CI N R Y Z E I nf usi o ns 
D uri n g T her a p y Me a n T ot al D a ys 
of S w elli n g D uri n g 
T her a p y 
CI N R Y Z E Pl ace b o CI N R Y Z E Pl ace b o CI N R Y Z E Pl ace b o CI N R Y Z E Pl ace b o CI N R Y Z E Pl ace b o 
7. 0 1 3. 0 1. 6 1. 6 2. 3 2. 6 6. 8 1 5. 0 9. 0 2 0. 8 
O L = o pe n -la bel 
a: 1 = mil d; 2 = m o derate; 3 =se vere 
Treat me nt - e mer ge nt A Es re p orte d i n c hil dre n i n t his st u d y  are s u m marize d bel o w: 
6- 1 1 ye ars of a ge:  [ADDRESS_76886] re p orte d 1 3 A Es (e xc oriati o n, hea dac he, H A E, i nfl ue nza, 
j oi nt i nj ur y , li m b i nj ur y , l y m p ha de n o pat h y , nasal c o n gesti o n, nas o p har y n gitis, p o or 
ve n o us access, p y re xia, varicella, a n d v o miti n g).  O nl y  1  e ve nt ( p yr e xia) was c o nsi dere d 
b y  t he I n vesti gat or t o be relate d t o st u d y  d r u g; t his e ve nt res ol ve d after a d urati o n of 
1da y .
1 2 - 1 7 ye ars of a ge:  3  s u bjects re p orte d 9 A Es (c o u g h, viral gastr oe nteritis, hea dac he, 
nas o p har y n gitis, p har y n g olar y n geal pai n, ras h, u p per res pi[INVESTIGATOR_1305] y  t ract i nfecti o n, uri nar y 
tract i nfecti o n, a n d v o miti n g).  N o ne of t hese e ve nts were c o nsi dere d relate d t o st u d y  
dr u g. 
St u dy L E V P [ADDRESS_76887] u d y  o f CI N R Y Z E f or t he pre ve nti o n of H A E attac ks ( Pr ot oc ol 
L E V P 2 0 0 6 -4), 2 3 pe diatric s u bjects were e nr olle d (a ge ra n ge: 3 t o 1 7 ye ars).  All [ADDRESS_76888] 1 d ose of CI N R Y Z E f or pre ve nti o n t hera p y . A s u m mar y  of t he efficac y 
res ults b y  p e diatric a ge gr o u p is pr o vi de d i n Ta ble 4.P P D   Wit h t he e x ce pti o n of 2 s u bjects 
a n d ), all pr o p h y lactic d oses of CI N R Y Z E were a d mi nistere d t o pe diatric 
s u b jects per pr ot oc ol ( 1 0 0 0 U e ver y 3 -7 da y s).  
Pri or t o e nr oll me nt, t he [ADDRESS_76889] u d y  r e p orte d a me dia n m o nt hl y  H A E attac k rate 
of 3. 0 (ra n ge: 0. 5- 2 8. 0).  D uri n g t he st u d y  w hile recei vi n g CI N R Y Z E pre ve nti o n t hera p y , 
pe diatric s u bjects e x perie nce d a me dia n m o nt hl y  a ttac k rate of 0. 3 9 (ra n ge: 0-3. 3 6), t he P P D P P D 
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 40 CONFIDENTIALmajority  (87%, 20/23) experienced ≤1HAE attack per month, and 22% (5/23) of children 
reported no attacks .  Thus, CINRYZE provided substantial clinical benefit in reducing the 
frequency  of angioedema attacks in children and was comparable to that observed in adults. 
Table 4. Summary  of Efficacy  Results for Pediatric Subjects (N=23) –
Frequency  of Angioedema Attacks A ge Group in Study  
LEVP [ADDRESS_76890] a
Mean (SD)
Median
Range0.69 (0.977)
0.69
0-1.380.35 (0.453)
0.16
0-1.330.71 (0.897)
0.[ADDRESS_76891], N (%) a
0 attacks
> 0 to ≤ 1 attack
> 1 to ≤ 2 attacks
> 2 to ≤ 3 attacks
> 3 to ≤ 4 attacks
> 4 attacks1 (50.0%)
0
1 (50.0%)
0
0
03 (33.3%)
5 (55.6%)
1 (11.1%)
0
0
01 (8.3%)
10 (83.3%)
0
0
1 (8.3%)
0
a:  Monthly attack rate for each subject = 30.4 x (total # of attacks ) / (last day of study drug –first day of 
study drug + 1).
In Study LEVP 2006 -4, the proportion of pediatric subjects (N=23) reporting a TEAE during 
the study  was 74% and similar to the pro portion reported in adults (79%).  The most common 
TEAE in the study  (and the most common TEAE in children) was upper respi[INVESTIGATOR_40947] (reported in 26% of children and 22% of adults).  Many of the TEAEs reported in 
children 6-[ADDRESS_76892] infections.  
Treatment -emergent AEs reported in children in this study  are summarized below:
2-5 years of age:  1/2 (50%) subjects reported treatment - emergent AEs of HAE (severe 
abdominal HAE attack) and upper respi[INVESTIGATOR_1092], both of which were 
considered to be not related to CI NRYZE. 
6-11 years of age:  8/9 (89%) subjects reported 50 treatment -emergent AEs, 46 of which 
were considered to be not related to CINRYZE.  Two subjects reported 4 treatment -
related AEs (dizziness, headache, mouth ulceration, and nausea). 
CI N R Y Z E ® ( C 1 esterase i n hi bit or [h u ma n] )
Pr ot oc ol 0 6 2 4 -3 0 1 w it h A me n d me nts 1 , 2, 3, a n d 4 
2 6 Ja n uar y 2 0 1 5 4 1 C O N FI D E N TI A L 1 2 - 1 7 years of a ge:  8 / 1 2 ( 6 7 %) s u bjects re p orte d 6 0 treat me nt -e mer ge nt A Es, 5 7 of 
w hic h were c o nsi dere d t o be n ot relate d t o CI N R Y Z E.  T w o s u bjects re p orte d 3 treat me nt -
relate d A Es (i nf usi o n site er y t he ma, metr orr ha gia, a n d p h ot ose nsiti vit y  reacti o n). 
Effic acy D at a f or Pe di atric S u bjects A ge d [ADDRESS_76893] ( ; fe male ) e nr olle d i n St u d y  L E V P 2 0 0 5- 1/ B i n t he 
6t o [ADDRESS_76894] u d y  L E V P 2 0 0 6 - 4 ( pre ve nti o n) 
a n d St u d y  L E V P 2 0 0 5 - 1/ A (treat me nt) .  T he ra n d o mize d treat me nt assi g n me nt f or t his s u bject 
was Place b o/ CI N R Y Z E a n d all a d mi nistrati o ns of CI N R Y Z E were [ADDRESS_76895] b o/ o n -de ma n d t hera p y  ( 8. 0 vs. 2 0. 0).  F urt her m ore, 
t he se verit y of attac ks was less ( 1. 5 vs 1. 7), t he d urati o n of attac ks was s h orter ( 2. 5vs. 3. 1 
da y s), a n d t he t otal da ys of s welli n g was c o nsi dera bl y l o wer ( 1 2. 0 vs 4 2) wit h CI N R Y Z E 
pre ve nti o n t hera p y  c o m pare d t o place b o/ o n -de ma n d t hera p y.  F e wer o pe n -la bel CI N R Y Z E 
i nf usi o ns f or treat me nt of ac ute H A E attac ks were a d mi nistere d t o t his s u bject w hile o n 
CI N R Y Z E c o m pare d wit h place b o/ o n -de ma n d t hera p y  ( 7. 0 vs. 2 8. 0). 
T a bl e 5. D et ail e d Effi c a c y  R e s ult s f or P e di atri c S u bj e ct –
St u d y L E V P 2 0 0 5 -1/ B                                        
O bser ve d N o. of 
Att ac ks D uri n g 
Ther a p y Me a n Se verit y a
of Att ac ks D uri n g 
T her a p y Me a n D ur ati o n 
of Att ac ks D uri n g 
T her a p y ( D a ys) N o. of O L CI N R Y Z E 
I nf usi o ns D uri n g 
T her a p y T ot al D a ys 
of S w elli n g D uri n g 
T her a p y 
CI N R Y Z E Pl ace b o CI N R Y Z E Pl ace b o CI N R Y Z E Pl ace b o CI N R Y Z E Pl ace b o CI N R Y Z E Pl ace b o
8 2 0 1. 5 1. 7 2. 5 3. 1 7 2 8 1 2 4 2 
a: 1 = mil d; 2 = m o derate; 3 =se vere 
Ta ble 6P P D 
descri bes t he de m o gra p hic, e x p os ure, a n d efficac y  d ata fr o m St u d y  L E V P [ADDRESS_76896] u d y , t hese 9 s u bjects 
re p orte d a me dia n m o nt hl y  H A E attac k rate of 3 (ra n ge:  2 -4).  D uri n g t he st u d y , t hese 
s u bjects e x perie nce d a me dia n m o nt hl y  a ttac k rate of 0. 1 6 (ra n ge:  0 -1. 3 3); t he maj orit y of 
s u bjects ( 8/ 9, 8 9 %) e x perie nce d ≤1 H A E attac k per m o nt h, a n d 3 3 % ( 3/ 9) re p orte d n o attac ks.   
I n ter ms of safet y, 8/ 9 ( 8 9 %) s u bjects re p orte d 5 0 treat me nt -e mer ge nt A Es, 4 6 of w hic h were 
c o nsi dere d t o be n ot relate d t o CI N R Y Z E.  As descri be d pre vi o usl y, tw o s u bjects re p orte d 4 
treat me nt -rel ate d A Es ( dizzi ness, hea dac he, m o ut h ulcerati o n, a n d na usea). P P D P P D 
CI N R Y Z E ® ( C 1 esterase i n hi bit or [h u ma n] )
Pr ot oc ol [ADDRESS_76897] s 6 -1 1 Y e ar s of A g e ( St u d y  L E V P 2 0 0 6 -4) 
S u bject I D A ge/ Ge n der Pre ve nti o n D ose D a ys o n St u d y Att ac ks per M o nt h 
B aseli ne O n St u d y 
F 1 0 0 0 U 5 8 2 4 0. 1 6 
F 1 0 0 0 U 2 4 6 2 0. 0 0 
M 1 0 0 0 U 3 0 1 2 0. 3 0 
F 1 0 0 0 U 6 9 7 4 0. 3 9 
M 1 0 0 0 U 3 4 4 4 1. 3 3 
F 1 0 0 0 U ( 7 5 0 da ys) 
2 0 0 0 U ( 9 0 da ys) 
1 0 0 0 U ( 8 3 da ys) [ADDRESS_76898] u d y R ati o n ale 
C urre nt i nter nati o nal c o nse ns us rec o m me n dati o ns f or H A E t hera p y  d o n ot pr o vi de s ufficie nt 
gra n ularit y acr oss all a ge gr o u ps a n d ca n n ot be u nc o n diti o nall y  a d o pte d f or pe diatric patie nts 
i n vari o us c o u ntries, d ue t o me dical a n d le gal iss ues (Wa h n et al., 2 0 1 2 ).  F urt her st u dies i n 
pe diatric s u bjects wit h H A E t hera pi[INVESTIGATOR_014] c urre ntl y  a p pr o ve d f or a d ults onl y ,will pr o vi de 
pe diatricia ns wit h t hera pe utic o pti o ns f or treati n g t heir patie nts.  R e gar dless, e x perts i n dicate 
t hat plas ma -deri ve d C [ADDRESS_76899] o ge ns a n d tra ne x a mic aci d are n ot 
rec o m me n de d ( Wa h n et al., 2 0 1 2 P P D 
).  
CI N R Y Z E I V (a d mi nistrati o n of 1 0 0 0 U e ver y  3 or 4 d a y s) was a p pr o ve d b y  t he U S F D A f or 
r o uti ne pr o p h yl a xis a gai nst a n gi oe de ma attac ks i n a d oles ce nt a n d a d ult patie nts wit h H A E i n 
Oct o ber 2 0 0 8.  C I N R Y Z E was als o a p pr o ve d t hr o u g h o ut t he E U, via t he Ce ntralize d 
Pr oce d ure, i n J u ne 2 0 1 1 f or treat me nt a n d pre -pr oce d ure pre ve nti o n of a n gi oe de ma attac ks i n 
a d ults a n d a d olesce nts wit h H A E, a n d r o uti ne pre ve nti o n of a n gi oe de ma attac ks i n a d ults a n d 
a d olesce nts wit h se vere a n d rec urre nt attac ks of H A E w h o are i nt olera nt t o or i ns ufficie ntl y 
pr otecte d b y  o ral pre ve nti o n treat me nts, or patie nts w h o are i na de q uatel y  m a na ge d wit h P P D 
P P D 
P P D 
P P D 
P P D 
P P D 
P P D 
P P D P P D 
P P D 
P P D 
P P D 
P P D P P D 
P P D 
P P D 
P P D 
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 43 CONFIDENTIALrepeated acute treatment.  CINRY ZE has also received marketing approval in Australia 
(March 2012), India (February  2013), Switzerland (May  2013), and Israel (August 2013) for 
all three indications (treatment, routine prevention, and pre-procedure prevention) in adults 
and adolescents (aswell as children 6 years and above in India) with HAE.  CINRYZE was 
approved in Canada (October 2012) for routine prevention against angioedema attacks in 
adults and adolescents with HAE.  
The HAE development program for IV CINRYZE included data in the pediatric population
that is among the largest for any C1 INH therapy  based on published 
literature.  However, 
further investigation is warranted to evaluate safet y, tolerability, and treatment effect in 
children 6to 11 years of age who require long term C1 INH replacement therap y due to the 
morbidity  imposed by [CONTACT_70560].  As of 07-Jun- 2013, in the US a total of 
110 patients less than 18 years of age with HAE are actively  receiving commercial 
CINRYZE.  Of 110 
patients, 26 children are 6 to 11years of age and 84children are 12 to 17 
yearsof age (data on file) .  
While CINRYZE has proven to be safe and effective in adults and adolescents, questions 
remain about the ideal pediatric dosing regimens ,particularl y for young and/or light-weigh t 
children.  Additional information with regards to the pharmacokinetics and dosing of 
CINRYZE in children (≥2 to <12 years of age) is currentl y being assessed in astudy  for the 
treatment of acute angioedema attacks (Protocol 0624- 203).  Dosing in study 0624-[ADDRESS_76900] weight category; 10
kg to 25 kg inclusive (500 U and 1000 U) and 
>25kg (1000 U and 1500 U).
Theaim of this study  is to assess the safety andtolerability ,relative efficacy , and PK/PD of 
two different doses (500 U and 1000 U) of CINRYZE administered by [CONTACT_70568] 6 to 11 years of age.  Consistent with 
the recent consensus on therapeutic strategies for children and adolescents with HAE (Wahn 
et al., 2012) , the current study  will account for differences in body  weight by [CONTACT_17801] 2 
fixed dosesof CINRYZE (500 U and 1000 U), and CINRYZE dosage will be relatedto 
plasma volume, body  surface area , and body  mass index .  The optim
aldose for this age group
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76901] comparison of the effectiveness and 
tolerability  of two dosing regimens.  In addition , the study  will provide supportive data on 
potential immunogenicity and quality  of life health status in this pediatric population , as well 
as prospective observational data on angioedema attack frequency  in the “ultra-orphan ”
6 to 
11 years of age subgrou p.
Detailed considerations regarding CINRYZE doses selected for this study  are presented in 
Section 5.1.
2.0 STUDY OBJECTIVES
The objectives of the study areas follows:
Primary  Objective
To assess the relative efficacy of two dose levels of CINRYZE (500 U and 
1000 U) administered by [CONTACT_70569]  3 or 4 days to prevent angioedema 
attacks in children 6 to 11 y ears of age.
Secondary  Objectives
To assess the safety  and tolerability  of two dose levels of CINRYZE administered 
by [CONTACT_70540] 6 to 11 y ears of age with HAE.
To characterize the PK and PDof CINRYZE administered by [CONTACT_70570] 6 to 11 y ears of age. 
To assess the immunogenicity  of CINRYZE following IV administration.
Other Object ive
To assess the impact of treatment on health status (quality  of life) in children 6 to 
11 years of age with HAE.
3.0 INVESTIGATIONAL PLAN
This multicenter, randomized, single -blind , dose-ranging, crossover study  will be conducted 
in multiple countries including the US,EU, and Latin America . Other countries/regions may 
be added if necessary  to complete enrollment. All study  sites, irrespective of geographic 
location, will conduct the study  in accordance with this study protocol and Good Clinical 
Practice (GCP )standards, including review and approval by [CONTACT_70571]® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 45 CONFIDENTIAL(IEC) .  Data from all sites will be pooled for purposes of analysis and will be reported in the 
final clinical study  report. 
Figure 1. Study Design
Potential subjects (≥6 to <12years of age) will have a screening evaluation the day prior to 
entering the study ’s baseline observation period.  Subjects with qualify ing angioedema attack 
rates, and who meet all other eligibility  criteria, will be enrolled and baseline observ ation 
period for at least 12 weeks .  
Throughout the study , an electronic study  diary (eDiary ) will be used to collect specific 
information regarding the subject’s symptoms of HAE.  The eDiary  will consist of two 
sections:  
(a) Section to record daily  if any elective procedures have been performed, signs and 
symptoms of angioedema attacks, triggers for angioedema attacks, medications used for 
the management of angioedema attacks, and interruptions in activities of daily  living due 
to an angioedema attack. Section (a) is to be completed by  [CONTACT_7071]/caregiver, and when 
possible, the same parent/caregiver should be responsible for completing this section of 
the eDiary  throughout the study .
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 46 CONFIDENTIAL(b) Section to record the impact of HAE on quality  of life (EQ-5D- Y).  Section (b) is to be 
completed by [CONTACT_70572] .  
Study  personnel will contact [CONTACT_7071]/caregiver by [CONTACT_70544]- weekly (Weeks 2, 4, 6, 8,
10,and 12) during the baseline observation period to discuss study  compliance (completion of 
the eDiary daily ) and to evaluate the subject’s angioedema attack frequency ( Schedule 1).
During the baseline obser vation period, subjects are allowed to remain on any prophylactic 
HAE 
therap y they were receiving prior to study  enrollment, if clinically  indicated.  However, 
it is recommended that consideration by [CONTACT_70573] [ADDRESS_76902] discontinue this therap y.  
In the event that during the 12 week s of baseline observation subjects do not meet the attack 
criteria qualify ing for randomization (≥1.0 angioedema attacks per month [average] that are 
moderate or severe or require acute treatment ), despi[INVESTIGATOR_70522], additional weeks of observations will be considered at the 
discretion of the Investigator and Sponsor to allow qualification for randomization and entry  
into the treatment periods of the study . In this case, subjects will maintain the same schedule 
of assessments by [CONTACT_70546] 1 again for the additional weeks of observation 
(Schedule 1) .
After the completion of the baseline observation period, subjects who remain eligible per 
study  criteria will be randomized to [ADDRESS_76903] dose of study 
drug in Treatment Period 1 (i.e., Dosing Day 1).  Twelve subjects will be randomized in this 
study .  There is no washout period between Treatment Period 1 and Treatment Period 2.  
Subjects are required to maintain their twice weekly  (every  3 or 4 day s) schedule between the 
last dose of study  drug in Treatment Period [ADDRESS_76904] dose in Treatment Period 2.
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 47 CONFIDENTIALSubjects and parents/caregivers will be blinded to treatment sequence and dose.  Study  site 
personnel, qualified home healthcare professionals, and the Sponsor will not be blind ed to 
treatment assignment and the dose of study  drug administered. Study  drug will be 
administered intravenously  by [CONTACT_70547], or by [CONTACT_70574]’s home or other agreed upon location.  
Alternativel y if allowed per local regulations, subjects who have been trained to self-
administer C1INH or who have a non -healthcare provider (e.g. ,parent) who has been trained 
to administer C1INH will be permitted to do sobased upon the request of the subject (and 
with approval of the parent(s)/legal guardian and the Investigator .  Note: self-administration 
will alway s occur under the supervision of a qualified healthcare professional at the study  site 
or the subject’s home (or other agreed upon location). Supervision by a qualified healthcare 
professional will include real time direct visual observation of the following: selection of the 
injection site, preparation of the injection site, insertion of the infusion device into the vein, 
study  drug infusion, removal of infusion device, compression and appl ying a bandage to the 
injection site, and disposal of all infusion materials.
The Investigator or designee will monitor and document study  compliance, tolerability of 
each CINRYZE dose, and adverse events.  The following doses of study  drug in each 
treatment period must be administered at the investigational site:  Dose 1 (Visits 1a and 1b), 
Dose 12 (Visits 12a and 12b) and Dose 24 (Visits 24a and 24b).  At these visits, subjects will 
also have other scheduled procedures performed (Schedules 2and 3).  For those subjects who 
are administered study  drug at a location other than the study  site,study  personnel will 
contact [CONTACT_7071]/car egiver by [CONTACT_70538] (Week 3after 
Dose 6 [Visits 6a and 6b] and Week 9after Dose 18 [Visits 18a and 18b]).  If study  drug is 
administe red at the site (Doses 6 and 18) , no telephone contact [CONTACT_70549].  
To the extent possible, subjects will postpone elective procedures (e.g., dental work) while 
participating in the study .  In the event a procedure cannot be postponed, parents /caregivers 
will notify  the Investigator and the infor mation will be recorded in the subject’s eCRF (see 
Section 6.8).
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76905] dose of 
study  drug as AEs (see Section 9.0).  
A post-treatment visit will be performed at the investigative site 1 week(±2 days) after the 
last dose of study  drug in Treatment Period [ADDRESS_76906] a blood sample for C1 INH antibody  testing collected 30 (±2) day s after the 
last dose of study  drug.  If a subject discon tinues prematurel y from treatment and/or the study , 
the Investigator will perform the Early Discontinuation Visit safet y procedures as soon as 
possible.  For those subjects who discontinue prematurely from treatment, every  effort should 
be made to complete all applicable protocol evaluations for the 1-month post-treatment 
follow -up visit (see Schedule 4
).  
Investigators will report all SAEs occurring up to [ADDRESS_76907] dose of study  drug to 
Shire VIROPHARMA and their respective Independent Reviewing Authority  (IRA) according 
to local reporting requirements.  In addition, SAEs with an onset more than [ADDRESS_76908] dose of study  drug should be reported if considered by [CONTACT_70575].  All suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) will be reported 
by [CONTACT_70576] 2001/20/EC, as applicable.  
Subjects will remain outpatient throughout the study.  Individual participation from 
screening through the completion of follow -up will be approximately  10 months.  Subjects 
will adhere to the protocol -defined schedule of clinical assessments and procedures as 
outlined below:
Schedule 1 –Clinical study  assessments during Screening and Baseline 
Observation Period (Weeks 1 to 12).
Schedule 2 –Clinical study  assessments during Treatment Period 1 (Visits 1a to 
24a).
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 49 CONFIDENTIALSchedule 3 –Clinical study  assessments during Treatment Period 2 (Visits 1b to 
24b).
Schedu le 4–Clinical study  assessments at Earl y Discontinuation, [ADDRESS_76909]
-treatment Follow -up Visits.
Schedule 5–Blood sample collection for PK/PD and post -treatment 
immunogenicit y assessments .
4.[ADDRESS_76910]:
1.Be a child (male or female), ≥6 to <12years of age at the time of screening . 
2.Have a confirmed diagnosis of Type I or Type II HAE and have a functional 
C1inhibitor (C1 INH) level less than 50% of normal.
3.Have a history  of ≥1.0 angioedema attacks per month (average) that are moderate1
or severe2or require acute treatment3during the [ADDRESS_76911] a parent(s)/legal guardian who is informed of the nature of the study  provide
written informed consent  for the child to participate in the study  before any  study -
specific procedures are performed (with assent from the child when appropriate).  
Additional Inclusion Criteria (Qualifying for Randomization)
6. Have experienced ≥1.0 angioedema attacks per month (average) that are moderate1
or severe2or require acute treatment3during the 12-week baseline observation 
period.
                                                
1Moderate:  Angioedema attack sign/ symptom(s) interferes with the subject’s ability to attend school or 
participate in family life and social /recreational activities.
2Severe:  Angioedema attack sign/ symptom(s) significantly limits the subject’s ability to attend school or 
participate in family life and social /recreational activities.
3‘Treatment’ refers specifically to standard of care therapi[INVESTIGATOR_70521] (e.g., 
C1INH, kallikrein inhibitor, bradykinin receptor antagonist).  Products used for the treatm ent of attack 
symptoms (e.g., analgesics, anti -emetics) do not qualify for this study inclusion criterion.
CI N R Y Z E ® ( C 1 esterase i n hi bit or [h u ma n] )
Pr ot oc ol [ADDRESS_76912] n ot: 
1. Ha ve a hist or y  of h y perc oa g ula bilit y  (a b n or mal bl o o d cl otti n g). 
2. Ha ve a dia g n osis of ac q uire d a n gi oe de ma or k n o w n t o ha ve C [ADDRESS_76913] or y  o f aller gic reacti o n t o C 1 I N H pr o d ucts, i ncl u di n g CI N R Y Z E ( or 
a n y  of t he c o m p o ne nts of CI N R Y Z E), or ot her bl o o d pr o d ucts. 
4. Be pre g na nt or breastfee di n g. 
5. Ha ve recei ve d a n i n vesti gati o nal dr u g ot her t ha n t h ose re q uire d f or pre ve nti o n or 
treat me nt of a n gi oe de ma attac ks wit hi n 3 0 da y s pri or t o scree ni n g. 
6. Ha ve, as deter mi ne d b y  t he I n vesti gat or a n d/ or t he S p o ns or’s me dical m o nit or, a n y 
s ur gical or me dical c o n diti o n t hat c o ul d i nterfere wit h t he a d mi nistrati o n of st u d y  
dr u g or i nter pretati o n of st u d y  res ults. 
A d diti o n al E xcl usi o n Criteri a ( Dis q u alifyi n g fr o m R a n d o miz ati o n) 
7. Ha ve a n y acti ve i nfecti o us ill ness or fe ver defi ne d as a n oral te m perat ure > 3 8 C 
( 1 0 0. 4 F), t y m pa nic > 3 8. 5 C ( 1 0 1. 3 F), a xillar y  > 3 8 C ( 1 0 0. 4 F), or rectal/c ore 
> 3 8. 5 C ( 1 0 1. 3 F) wit hi n [ADDRESS_76914] s u bjects (a ges a n d y ears ol d) recei ve d [ADDRESS_76915] u d ies L E V P 2 0 0 5 -1/ B a n d 
L E V P 2 0 0 6 -4, w here all pe diatric s u bjects ha d a cli nicall y si g nifica nt re d ucti o n i n t he n u m ber 
of a n gi oe de ma attac k sw hile recei vi n g 1 0 0 0 U of I V  C I N R Y Z E e ver y  3 -7 da y s (see Ta ble 5
a n d Ta ble 6). P P D 
 T his d osi n g re gi me n ha d a fa v ora b le safet y pr ofile i n c hil dre n w he n 
a d mi nister ed f or r o uti ne pre ve nti o n of a n gi oe de ma attac ks. P P D 
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 51 CONFIDENTIALAlthough the data support that higher doses of CINRYZE are not necessary for subjects in the 
6 to 11year age group, the efficacy  of a lower dose (500 U every  3-4days) has not been 
evaluated in this “ultra-orphan ”subgroup .  The proposed study  will provide additional data on 
a dosage range of CINRYZE for the prevention of angioedema attacks in children 6 to 11 
years of age.  
5.2 Randomization
Twelve subjects 
will be randomized to one of two treatment sequences, with each sequence 
consisting of two 12- week treatment periods.  Randomization will occur on Dosing Day 1 
(Visit 1a)of Treatment Period 1.  Each investigative site will receive a randomization 
schedule which will be used to assign subjects at that site to one of two sequences (A/B or 
B/A), with equal probability .Treatment A will be 500 U CINRYZE administered 
intravenously  twice weekly  (every  3 or 4 day s) for 12 weeks and Treatment B will be 1000 U 
CINRYZE ad
ministered intravenously  twice weekly  (every  3 or 4 day s) for [ADDRESS_76916]’s home .Alterna tively  if allowed per local regulations, subjects who have been 
trained to self-administer C1INH or who have a non-healthcare provider (e.g.,parent) who 
has been trained to administer C1INH will be permitted to do so based upon the request of 
the subjec t (and with approval of the parent(s)/legal guardian and the Investigator )
.  Note: 
self-administration will alway s occur under the supervision of a qualified healthcare 
professional at the study  site or the subject’s home (or other agreed upon location). 
Supervision by a  q ualified healthcare professional will include real time direct visual 
observation of the following: selection of the injection site, preparation of the injection site, 
insertion of the infusion device into the vein, study  drug infusion, removal of infusion device ,
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76917] ying a bandage to theinjection site, and disposal of all infusion 
materials.
For Treatment A(500 U CINRYZE dose), an additional vial of 5 mL sterile water for 
injection (SWFI) will be added to the 5 mL vial of reconstituted CINRYZE to make a total 
volume of 10 mL.  For Treatment B(1000 U CINRYZE dose), two 5 mL vials of 
reconstituted CINRYZE will make a total volume of 10mL.  CINRYZE will be administered 
intravenously  as a single 10-mL injection and at a rate of approximately  1 mL  (50-100 U) per 
minute ,as tolerated.
The following doses of study  drug in each treatment period must be administered at the 
investigational site:  Dose 1 (Visits 1a and 1b), Dose 12 (Visits 12a and 12b) and Dose 24 
(Visits 24a and 24b).  At these visits, subjects will also have other scheduled procedures 
performed (Schedules 2and 3).  For each dose administered, date and time at start of infusion 
and the date and time atcompleti on of infusion will be recorded in the eCRF .  An y departure 
from the expected dosing regimen will be recorded in the eCRF.
5.4 Blinding
This is a single -blind study .  Subjects and parents/caregivers will be blinded to the treatment 
administered.  Study site personnel, qualified home healthcare professionals, and the Sponsor 
will not be blinded to dose and treatment sequence.  
To maintain the treatment blind (for subjects and parent s/caregivers) , each dose of study  drug 
will consist of a single IV inje ction (total volume of 10mL; see Section 
5.3). 
5.[ADDRESS_76918]-treatment follow - up visit (see Schedule 4).  Other enrolled 
subjects will continue with study  drug administration and procedures
. 
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 53 CONFIDENTIAL5.5.2 Thrombotic or Thromboembolic Event
If a T/TE event occurs in any subject, no further enrollment will occur pending a complete 
review of all available data.  Other enrolled subjects will continue with study  drug 
administration and procedures.  Following a safet y review of the T/TE event, study 
enrollment may be restarted if the medical monitor determines that the event was unrelated or 
unlikely  to be related to study  drug or other C1 inhibitors, which may  have been administered 
for an angioedema attack.
If a T/TE event occurs in any subject, study  drug administration for that subject will be 
interrupted; however, other study  procedures will continue, as clinically  appropriate .  
Investigators will comply  with protocol -defined algorithms to assist in the diagnosis and 
management of all suspected T/TE events (see Appendix II).  Following a complete medical 
review by [CONTACT_1034], in conjunction with the Investigator, dosing with study  drug may be 
resumed to complete a total of 24doses in the treatment period that was interrupted.  Study 
procedures including PK/PD testing will resume relative to dosing.  If study  drug cannot be 
restarted within [ADDRESS_76919] will be discontinued from 
treatment and will follow the schedule of assessments for early discontinuation (see 
Schedule 4).
6.[ADDRESS_76920] 
been explained and written permission to 
participate has been voluntarily  granted by [CONTACT_7071]/legal guardian and assent has been 
provided by [CONTACT_423] (to the extent that is compatible with the subject’s understanding )(see 
Section 14.0) .  Schedules 1, 2, 3, and4provide details of study  procedures for clinical study  
assessments and Schedule 5provides timing of blood sampling for PK/PDand post-treatment 
immunogenicit y testing . 
6.[ADDRESS_76921] remains eligible for study  participation.   
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76922] been present/active within 1year prior to enroll ment 
will be recorded in the eCRF regardless of clinical relevance or presence at study  start.  
Medical history  findings that have not been present within 1year prior to enrollment will be 
recorded if deemed clinically  relevant by [CONTACT_70577] .  The 
medical history is to include any  history  of allergic reactions to drugs.   
The Investigator or designee will perform physical examinations at the time points specified 
in Schedules 2, 3, and [ADDRESS_76923] practices at the study  site. Clinically  significant physical examination 
abnormalities observed prior to dosing with study drug also will be recorded in the medical 
history  section of the eCRF .  Any  new or worsening clinically  significant abnormalit y 
observed any time after the start of study  drug administration should be recorded as an AE 
(see Section 9.0).  
Body weight and height will be measured at the time points specified in Schedules 2and 3.  
Measurements should be performed wit hout shoes and underclothes onl yand measured by  [CONTACT_70578] (if possible) .
6.1.1 HAE History
The following information associated with HAE history  will be recorded in 
theeCRF at the 
screening visit (NOTE:  the attack rate may be estimated based on subject or parent/caregiver
recall as well as the subject 's medical records):  
HAE Type ( Ior II).
Any first-degree blood relative (i.e.,mother , father, sibling) diagnosed with HAE.
(yes/no).  If yes, provide the relationship of first -degree blood relative (s).
Any therapy  received during the 9months prior to screening for management of 
HAE (yes/no) (see Section 6.3.1).
Total number, typi[INVESTIGATOR_70526] ,average overall duration (days), and average 
overall 
severit y of HAE attacks experienced during the 3months prior to screenin g
(see Section 6.10.1 for definition of severity ).
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 55 CONFIDENTIAL6.2 Vital Signs
Blood pressure and heart rate will be measured at the time points specified in Schedules 2,3
and 4
.  Bod y temperature will be measured prior to randomization at Visit 1a.  During the 
study , additional vital signs measurements will be performed if clinically  indicated.  
Vital 
signs performed on dosing daysshould be obtained prior (within 60minutes) tothe start of 
the injection andbetween [ADDRESS_76924] vital signs prior to any blood sample 
collection.   
6.3 Prior and Concomitant Medications
Prior and concomitant medications to be recorded will include prescription medications, 
blood products (e.g., albumin, packed red blood cells, whole blood, fresh frozen plasma, 
platelets), dietary  supplements/vitamins, electroly te supplementation, and over-the-counter 
medications.  Topi[INVESTIGATOR_70527].
6.3.[ADDRESS_76925] in the eDiary any medications 
taken by [CONTACT_70579] t for the management of angioedema attacks during the baseline 
observation period. 
Any therap y received during the 9 months prior to screening for the management of 
angioedema attacks should be recorded, including overall start and stop dates if known, and 
the HAE indication (i.e., long-term prevention , acute treatment, short-term prevention).  For 
anymedication used in the management ofHAE that hasa start date prior to Treatment 
Period [ADDRESS_76926] dose of study  drug in Treatment Period 1 should be entere d into the eCRF.  Any 
subsequent use of this medication should be recorded as a concomitant medication with a new 
start date.
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76927] the start/stop dates, dose, unit, frequency , route of 
administration, and indication (if known) in the subject’s eCRF.  For medications not 
associated with the management of HAE, study personnel will record the start/stop dates, 
route of administration, and indication for which the medication was administered in the 
subject’s eCRF.
6.3.3 Prohibited Medications
Use of C1 INH therap y (other than study  drug) for prophy laxis against angioedema attacks is 
prohibited during the study after completion of the baseline observation period. At least [ADDRESS_76928] 6 weeks of the observation period, if clinically  indicated. If these medications 
cannot be discontinued, stable doses should be us ed during Treatment Periods 1 and 2. 
Details on the management of acute angioedema attacks arediscussed in Section 6.10.
6.4 Nonpharmacologic Treatments and Procedures
Nonpharmacologic treatments and procedures (e.g., surgical, diagnostic , or dental) that occur 
during the baseline observation period through 1-week post-treatment will be recorded in the 
eCRF .
6.[ADDRESS_76929] blood samples collected for routine clinical laboratory  testing at the time 
points specified in Schedules 
1, 2, 3 and 4.  Testing will be performed at a Central Lab oratory , 
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76930].  The following clinical labora tory 
parameters will be anal yzed :
Hematology: 
Dosing Visits 1a(pre-dose), 12a, 1b (pre-dose), 12b, 24b, and 1-week 
post-treatment (or if prematurely discontinued):   CBC consisting of WBC 
and differential counts and percentages, RBC count, hemoglobin, 
hematocrit, and platelet count.
Clinical Chemistry:
Dosing Visits 1a (pre-dose), 12a, 1b (pre-dose), 12b, 24b, and 1-week 
post-treatment (or if prematurely discontinued):   Blood urea nitrogen 
(BUN), creatinine, glucose, sodium, potassium, chloride, carbon dioxide 
(CO 2), aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
alkaline phosphatase (ALP), creatine phosphokinase (CPK), total bilirubin, 
calcium, phosphorus, total protein, and albumin.
Coagulation:
Dosing Visits 1a (pre-dose), 12a, 1b (pre-dose), 12b, 24b, and 1-week 
post-treatment (or if prematurely discontinued):   Prothrombin time (PT), 
international normalized ratio (INR),and activated partial thromboplastin 
time (aPTT).
Virology:
Dosing Visit 1a (pre-dose) and 1-week post-treatment (or if prematurely 
discontinued )
:  Human immunodeficiency  virus (single assay 
antibody /Western Blot) and hepatitis (Hepatitis B Surface Antigen, 
Hepatitis C Antibody ).
For all females who have reached menarche , urine pregnancy testing will be performed at 
the site at the time points specified in Schedules 2 and 4.
Additional clinical laboratory  testing may be performed if clinicall y indicated, at the 
discretion of the Investigator ,and may be sent to central laboratory  or performed locally , and 
allresults will be recorded.
6.6 Pharmacokinetic , Pharmacodynamic , and C1INH Antibody Analyses
Blood samples for the determination of plasma concentrations of C1INH antigen, functional 
C1INH, and C4 complement will be collected from subjects during each treatment period as 
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 58 CONFIDENTIALshown in Schedule 5.  In addition, plasma samples collected prior to the dose of CINRYZE on 
Visit 1a (Dose 1 of Treatment Period 1), and Visit 1b (Dose 1 of Treatment Period 2), will be 
analyzed for C1INH antibodies (see Schedules 2and 3).  Additional blood samples for C1 
INH antibody  testing will be collected [ADDRESS_76931]-treatment (or if prematurely  discontinued) 
and [ADDRESS_76932] dose of study  drug (see Schedule s 4and 5).  
NOTE:   If a subject presents to the sitewith an angioedema attack, every  effort should be 
made to obtain a PKblood sample prior to any  treatment.  In addition, if the subject is treated 
with comme rcial C1 INH, every  effort should be made to obtain a 1-hour post-treatment 
sample .  These samples will be anal yzed for C1 INH antigen andfunctional C1 INH activit y.
The actual date and time of each sample collection will be recorded . 
 Plasma samples for the 
determination of antigenic C1 INH, functional C1INH, complement C4 concentrations, and 
C1INH antibodies will be analyzed using validated methodology .  All samples , except for 
incurred samples, will be processed according to the procedure outlined in Appendix I . 
Selected samples may be analyzed to investigate incurred sample reproducibility  (ISR) of the 
bioanaly tical methods and/or incurred sample stability  (ISS).  These analy ses are only to 
investigate the reproducibil ity of the bioanal ytical methods used to determine concentrations 
of antigenic C1INH and functional C1INH activity  in study  samples to investigate the 
stability  of incurred samples.  All ISR and ISS results collected will be reported in a separate 
table in the bioanal ytical report.  All samples will be disposed of at the conclusion of the 
study .  Details of disposal will be documented and maintained with the study  file at the 
analytical laboratory .
6.[ADDRESS_76933] approxima tely 172 mLof blood collected for clinical safet y laboratory  
testing (hematology , chemistry , and coagulation), PK/PD , and immunogenicity  (C1INH 
antibodies )assessments during the study .
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76934] of their ability . To the extent possible, subjects will postpone elective procedures (e.g., 
dental work) while participa ting in the study .  In the event a procedure cannot be postponed, 
the parent/caregiver will notify  the Investigator and the information will be recorded in the 
eCRF (see Section 6.4).   
6.9 Electronic Study Diar y(eDiary)
Throughout the trial, an eDiary  will be used to collect specific information regarding the 
subject’s sy mptoms of HAE.
  The eDiary  will consist of two sections:
(a) Section to record daily  if any elective procedures have been performed, signs and 
symptoms of angioedema attacks, triggers for angioedema attacks, medications used for 
the management of angioedema attacks, and interruptions in activities of daily  living due 
to an angioedema attack.  Section (a) is to be completed by [CONTACT_7071]/caregiver, and when 
possible, the same parent/caregiver should be responsible for completing this section of 
the eDiary  throughout the study .
(b) Section to record the impact of HAE on quality  of life (EQ-5D-Y, see Section 6.11.1).  
Section (b) is to be completed by [CONTACT_70580] .  
Atthe screening visit,study  personnel will instruct subjects and parents/caregiver show to 
complete the eDiary .  The diary  will be completed on each day during the baseline 
observation period and Treatment P eriods [ADDRESS_76935]’s eDiary for completeness and accuracy  at each 
visit.  TheeDiary is intended to be used by [CONTACT_70581], inpatient records (if applicable), and any other study -specific records as source 
documentation .  
Details about the use of the eDiary  are provided in a separa te study  manual.
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76936] -reported (or parent/caregiver -reported) 
indication of swelling or pain at any location following a report of no swelling or pain on the 
previous day (i.e., there must be a full symptom -free calendar day preceding the onset of 
symptoms for an attack to be considered a new attack).  Therefore, 
Attacks that progress from one site to another will be considered a single attack,
Attacks that begin to regress and then worsen before complete resolution will be 
considered one attack, and
Attacks that begin, appear to resolve, and then reappear without a s ymptom -free 
calendar day  reported after the appearance of resolution will also be considered 
one attack.
NOTE:   An angioedema attack does NOT include swelling due to trauma and symmetrical 
non-painful swelling of the lower extremities.
6.10.1 Recording of 
Angioedema Attacks
During the observation period and both treatment periods, parents /caregivers will use the 
eDiary  each day  to record any symptoms or occurrences of an angioedema attack experienced 
by [CONTACT_423] .  The Investigator will complete a separate angioedema attack eCRF for each 
attack based upon their review of the data in the eDiary and include:
Characterization of whether swelling or pain is (indicate all that appl y):
Mucosal (phary ngeal, lary ngeal, gastrointestinal, genitourinary )
Non-mucosal (truncal, external, facial)
Location (site) of the swelling or pain (indicate all that apply ):
Upper airway  (includes lary ngeal or pha ryngeal)
NOTE: phary ngeal or oral swelling that results in airway  compromise will 
be classified as a lary ngeal attack
Gastrointestinal/abdominal (including symptoms of pain, nausea, vomiting, 
swelling, and/or change in bowel habits )
Genitourinary  (includin g scrotum or vulva)
Facial
Extremity  or peripheral (e.g., buttocks, external head/neck, trunk)
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 61 CONFIDENTIALSeverity  (intensity ) of the sign/s ymptom at each location listed:
None
Mild:  the angioedema attack sign/ symptom(s) is noticeable but is easily 
tolerated b y the subject and does not interfere with routine activities.
Moderate:  angioedema attack sign/ symptom(s) interferes with the 
subject’s ability  to attend school or participate in family  life and 
social/ recreational activities.
Severe:  the angioedema attack sign/symptom(s) significantl y limits the 
subject’s ability  to attend school or participate in family  life and 
social/ recreational activities.
Angioedema attack trigger (s)
Answer the question, “Was treatment administered for the attack?”   If yes, record 
treatm ent administered.
In addition to recording the above informati on, study  personnel will report any angioedema 
attack that occurs after the first dose of stud y drug as an AE (see Section 9.0).  
6.10.[ADDRESS_76937] experiences an acute angioedema attack at any time during study  that in the 
opi[INVESTIGATOR_70528], the choice of acute 
treatment will be left to the Investigator’ s discretion .  Whereappropriate, CINRYZE can be 
provided for acute treatment of angioedema attacks. Acute treatment(s) for angioedema 
attacks 
should be recorded in the eCRF (see Sections 6.3.2 and 6.4).
6.10.[ADDRESS_76938] adhering to the study
schedule , regardless of whether C1INH therapy or other products were administered to treat 
the attack.  
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 62 CONFIDENTIAL6.11 Quality of Life Measurements
6.11.1 Health -related Quality of Life (EQ-5D-Y)
EQ-5D-Y1(Youth version of EQ-5D) is a descriptive system of youth health -related quality 
of life states consisting of five dimensions, each of which can have one of three responses . 
The responses record the level of severit y within a particular EQ-5D dimension.  EQ-5D- Y is 
not intended for use in children 6 years of age(Noyes and Edwards, 2011 ); however in this 
study  all subjects (6 to 11 years of age and where translated language version isavailable )
will be assessed .  TheEQ-5D- Y will be completed by [CONTACT_70582] 1, 2, 3and 4, as well as on each day that a subject experiences signs or 
symptoms of an angioedema attack (see Section 6.9).  
Details 
about the use and administration of the EQ-5D- Y questionnaire are provided in a 
separate study  manual .
6.12 Discontinuation From Treatment and/or Study
When a subject is discontinued from treatment and/or study , Early Discontinuation Visit 
procedures will be performed (see Schedule 4). For those subjects who discontinue 
prematurel yfrom treatment
, every  effort should be made to complete protocol evaluations for 
the1-month p ost-treatment follow -up visit .  
For those subjects who enter the observation period but discontinue prior to randomization or 
who discontinue after randomization but prior to receiving study drug, the following 
information will be 
recorded in the eCRF:
Demographic information
Inclusion/exclusion information
HAE history  and HAE medications for the 9months prior to the observation period 
and also for the duration of the observation period
Angioedema attack data (all attributes of the attacks such as locatio n, severit y, pain 
assessment, possible trigger, treatment received, missed school)
                                                
1EQ-5D™ is a trade mark of the EuroQol Group.
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 63 CONFIDENTIALEQ-5D- Y data
Reason for not receiving study  drug(e.g., not randomized as subject failed to meet 
qualify ing attack criteria or Investigator concern regarding subject’s or 
parent/caregiver’s compliance with study  procedures) 
No additional study  procedures or follow -up will be performed on subjects who discontinue 
prior to receiving a dose of study  drug.
6.12.[ADDRESS_76939] may be discontinued prematurel y from study  drug treatment for the following 
reasons:
Withdrawal by  [CONTACT_1130] (i.e., assent withdrawn) [specify  reason in the eCRF]
Withdrawal by  [CONTACT_7078]/guardian [specify  reason in the eCRF]
Adverse event (which in the opi[INVESTIGATOR_689], due to the nature and 
severit y, requires discontinuation from treatment)
Lost to f ollow -up
Physician decision (i.e., Investigator decision based on protocol violation, 
assessment that it is not in the subject’s best interest to continue, or other reason) 
[specify  reason in the eCRF ]
Sponsor decision [specify reason in the eCRF ]
Subjects who discontinue study  drug due to an AE will be followed until the event is either 
resolved or assessed as stable b y the Investigator .
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76940] may  be discontinued prematurely  from the study  for the following reasons:
Withdrawal by  [CONTACT_1130] (i.e., assent withdrawn) [specify  reason in the eCRF]
Withdrawal by  [CONTACT_7078]/guardian [specify  reason in the eCRF]
Lost to follow -up
Death
Physician decision (i.e., Investiga tordecision based on protocol violation, 
assessment that it is not in the subject’s best interest to continue, or other reason) 
[specify  reason in the eCRF ]
Sponsor decision [specify reason in the eCRF ]
7.[ADDRESS_76941] finished the study .  This will facilitate timely 
reporting of study  results to the European Medicines Agency ’s Paediatric Committee after [ADDRESS_76942] completed the study  as agreed in the Pediatric Investigation Plan. A final CSR 
will be completed after 12 subjects finish the study .   
7.1 Sample Size
This study  is designed to assess the safety , tolerability , and relative efficacy  of two different 
doses (500 U and 1000 U) of CINRYZE as prevention therap y for angioedema attacks in 
children [ADDRESS_76943] a history  of angioedema attacks appropriate to meet study  inclusion criteria
(Caballero, 2012), this number is considered a reasonable target with respect to the ability  to 
enroll eligible subjects. 
7.2 Populatio ns
Data will be collected and summarized for allsubjects randomized and treated with study 
drug.
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76944] in each treatment period: 
Number of angioedema attacks, normalized to a 12- week treatment period
Cumulative Attack Severity .  This score is the sum of the maximum symptom 
severit y recorded for each angioedema attack in a treatment period.  
Cumulative Daily  Severity .  This score is the sum of the severity  scores recorded 
for every  day of reported sy mptoms in a treatment period.  
Time (measured in days from the first dose of study  drug in a treatment period) to 
the first angioedema attack reported in that treatment period.
Change from pre-to post -dose in C1 INH functional activity , C1 INH antigen, and 
C4 levels.
Number of angioedema attacks requiring acute treatment during each treatment 
period.
The endpoints based on attack severit y are further defined with the following example:
Study 
DaySymptoms 
PresentMaximuma
Symptom  
Severity Symptom  
Severity 
ScoreAttack 
NumberMaximumb
Attack 
Severity Daily 
Severity 
1 Yes Moderate 2 1 - 2
2 Yes Moderate 2 2 2
3 No
4 Yes Mild 1 2 - 1
5 Yes Severe 3 - 3
6 Yes Moderate 2 3 2
7 No
8 Yes Moderate 2 3 - 2
9 Yes Severe 3 - 3
10 Yes Moderate 2 - 2
11 Yes Moderate 2 3 2
a: Maximum Severit y across all anatomic locations on the corresponding study  day.
b: Maximum Severit y across all anatomic locations and day s with symptoms for the corresponding attack.
In this hypothetical example, a patient recorded [ADDRESS_76945] day of symptoms and is derived as Mild, Moderate, or 
Severe.  Coding these categories as Mild=1, Moderate=2, and Severe=3 and summing over 
the three unique attacks, yields a Cumulative Attack Severit y of 8.  Finally , summing the 
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76946] to these defined endpoints, this hypothetical eleven -day symptom diary 
would be quantitatively  described b y:
Endpoint Value
Number of Attac ks [ADDRESS_76947] of superiority  (1000 U 
vs. 500 U) conducted at α=0.10.  
7.4 Safety Analysis
The following will be assessed during the study :
Safety  and tolerability , including:
adverse events b y dose group
adverse events b y exposure (dose normalized to body weight [U/kg])
adverse events by [CONTACT_70551] (e.g., during administration of study  drug 
or within 24 hours after the end of injection of study  drug) 
Summary  statistics and changes from baseline to post-baseline for laboratory 
testing and vital signs by  [CONTACT_70583].
Results of C1 INH antibody  testing will be reported for individual subjects and 
summarized as appropriate. 
7.5 Other Endpoints
Results of the EQ-5D-Y health status questionnaire will bepresented in accordance with the 
EQ-5D-3L User Guide (version 4.01), and adapted as appropriate for the youth version.
7.6 Pharmacokinetic and Pharmacodynamic Analyses
Concentrations of C1INH antigen, functional C1INH activit y, and complement C4 for 
individ ual subjects will be determined.  Results will be summarized using descriptive 
                                                
1EQ-5D-3L User Guide: Basic information on how to use the EQ-5D-3L questionnaire .  Version 4.0, April 
2011.  Published by [CONTACT_70552].
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 67 CONFIDENTIALstatistics (number, mean, standard deviation, median, minimum, and maximum) for values at 
each time point and for change from baseline at each post- injection time.
PK/PD 
analy ses will be performed based on correlation of plasma concentrations of C1INH 
antigen, functional C1INH, and C4 complement in conjunction with various safet y 
parameters (e.g., selected AEs, clinical laboratory results, antibodies generation, frequency , 
severit y, or anatomic location of the angioedema attack, etc.).  Correlations that will be 
analyzed will be determined based on observed data.
8.0 DRUG SUPPLIES
CINRYZE and supplies required for CINRYZE reconstitution will be provided by [CONTACT_429].
8.1 How Supplied
CINRYZE is supplied as a lyophilized powder of 500 U (C1 INH)/vial.  The vial of 
CINRYZE also contains the following inactive ingredients:  trisodium citrate, sodium 
chloride, L-Valine, L -Alanine, L -Threonine, and sucrose.
CINRYZE product and sterile wate r for injection(s) (SWFI) approved for commercial 
distribution in the US will be used at all sites.  The US sourced vials of CINRYZE will be 
stored at 2oC–25oC (36oF –77oF) and protected from light.  Do not freeze.
8.1.1 Reconstitution of 
CINRYZE for Intravenous Infusion
Each vial of CINRYZE will be reconstituted with 5 mL of SWFI .  The following supplies will 
be required for reconstitution using aseptic technique:  [LOCATION_002] Pharmacopeia (USP) 
SWFI , disinfecting strips, Mix2Vial ®transfer device, and silicone -free disposable sy
ringes.  
Each infusion will require reconstitution of one (1) or two (2) 500 U vials depending on 
treatment scheduled (Treatment A[500 U]or Treatment B[1000 U]; see separate Pharmacy 
Manual ).  The solution must be used within 3 hours of reconstitution .
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76948]’s eCRF .  In addition, 
records must be kept on when and how manystudy  drug vials weredispensed foreach 
individual subject in the trial.  Reasons for departure from the expected dosing regimen must 
also be recorded in both source documents and the eCRF .  Sponsor representatives will 
review drug accountability  on an ongoing basis throughout the study .  An overall summary  of 
all drug supplies received and used must be recorded on the appropriate forms and signed by 
[CONTACT_70584] [INVESTIGATOR_70529] .  Wr itten records 
will be maintained documenting a final accounting of study  drug received at the 
investigational site and study  drug vials dispensed to subjects.  All unopened /
unused /used
study  drug vials will be returned by [CONTACT_70585] (CRA) to the central 
distributor or destroy ed by [CONTACT_70586]. 
8.[ADDRESS_76949] participating in a 
clinical study  withstudy drug, regardless of causal relationship.  An AE includes any 
condition that (1) was not present prior to study  therap y but appeared following initiation of 
study  therap y or (2) was present prior to study therap y, but worsened in severity  and/or 
frequency following initiation of study  therap y.  NOTE:  In this study , angioedema attacks 
after the first dose of study  drug will be reported as AEs .  
Adverse events will be monitored from thefirst dose of study  drug inTreatment Period [ADDRESS_76950] with any AE until the 
event is either resolved or assessed as stable and, where appropriate, additional written reports 
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 69 CONFIDENTIALwill beprovided.  The Investigator will evaluate and report the onset date, outcom e, end date, 
duration (if <24hours), severity  (intensity ), relationship to study  drug, actions taken, and 
determination of seriousness for each AE.  In addition, the Investigator will report if the AE 
onset occurred during study  drug administration or within 24 hours following completion of 
study  drug administration.  
9.1 Severity (Intensity) Assessment
The severit y (intensit y) of AEs will be assessed according to the following definitions:
Mild:  The AE is noticeable to the subject but is easily  tolerated and does not 
interfere with routine activity .  The AE may  or may  not require medication therapy 
or other therap y.
Moderate:  The AE interferes with routine activity  but usuall y responds to 
medication therap y or other therap y.
Severe:  The AE significantly  limits the subject's ability  to perform routine 
activities and may  not respond to medication therapy  or other therapy .  
If the intensity  of an AE changes over time, the maximum intensity  experienced should be 
recorded.  
9.[ADDRESS_76951] been caused by [CONTACT_5257], as 
follows:
Definitely Related:   The event follows a reasonable temporal sequence relative to 
the administration of the study  drug, and there is no other cause to explain the 
event (or the event reappears after repeat exposure [positive re -challe nge]). 
Probably Related:   The event follows a reasonable temporal sequence relative to 
the administration of the study  drug, and the event is more likely  to be explained 
by [CONTACT_70587] b y another cause. 
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 70 CONFIDENTIALPossibly Related:   The event follows a reasonable temporal sequence relative to 
the administration of the study  drug, but could have been due to another cause 
such as the subject’s clinical state or other drugs/therapi[INVESTIGATOR_014]. 
Not Associated With the Use of Study Drug
There is not a reasonable possibi lity that the event may have been caused by [CONTACT_24384], 
as follows:
Unlikely to be Related:   The temporal sequence of the event relative to the 
administration of the study  drug makes a causal connection improbable, or the 
event could plausibly  be expla ined by [CONTACT_70588]’s clinical 
state or other drugs/therapi[INVESTIGATOR_014].
Not Related:   Sufficient information exists to indicate that the event is unrelated 
to the study  drug.  For example, the event does not follow a reasonable temporal 
sequen ce relative to the administration of the study  drug, a causal relationship is 
considered biologically  implausible, or the event is readil y explained by [CONTACT_70589]’s clinical state or other drugs/therapi[INVESTIGATOR_014].
9.3 Serious Adverse Events
An S AE is any  AE that results in any  of the following outcomes:
Death.
A life-threatening event (refers to any AE that places the subject at immediate risk 
of death from the event as it occurred; a life-threatening event does not include an 
event that, had it occurred in a more severe form, might have caused death, but as 
it actually  occurred, did not create an immediate risk of death).
Inpatient hospi[INVESTIGATOR_1324] 
(hospi[INVESTIGATOR_70530]).  Emergency  room (ER) visits 
are not considered serious until any of the other serious outcomes are met.  Any 
elective hospi[INVESTIGATOR_272] a pre-existing condition that has not worsened does not 
constitute an SAE.
A persistent or significant incapacity  or substantial disruption of the ability  to 
conduct normal life functions.
A congenital anomal y/birth defect.
Other medicall y important events that, based upon appropriate medical judgment, 
jeopardize the subject or may require intervention to prevent any of the above 
serious outcomes (e.g., a subject is treated in the ER but is not admitted to the 
hospi[INVESTIGATOR_307]).
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76952] dose of study  drug 
should be reported if considered by [CONTACT_70590] (i.e., possibly , 
probably , or definitely  associated with the use of study  drug; see Section 9.2).
If an AE is assessed as serious, all SAE information must be recorded using the SAE form 
(paper or electronic) provided by [CONTACT_1034].  Additional follow -up information (e.g., test 
results, physician narrative, discharge summary , autops y findings) will be provided to 
supplement the SAE report, with additional follow -up SAE reports submitted as needed.  A 
copy  of all initial and follow -up SAE reports, including supplemental documents, will be 
maintained by  [CONTACT_1034].  
All suspe cted unexpected serious adverse reactions (S[LOCATION_003]Rs) will be reported by [CONTACT_70591] 
2001/20/EC, US FDA regulation 21CFR312.32, and additional relevant regulatory  authorities
in accordance with country- specific regulations , as applicable.
9.3.[ADDRESS_76953] label will serve as the Reference Safety  Information (RSI ).For 
study  sites in countries where CINRYZE has not received marketing approval, the compan y 
core data sheet will serve as the RSI .
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 72 CONFIDENTIAL9.4 Other Reportable Events
Certain events that occur in the absence of an AE should be reported to Shire VIROPHARMA
Drug Safet y as other reportable events using the Other Reportable Information form (paper or 
electronic) provided b y the Sponsor.  These include the following:
Pregnancy  exposure (subject becomes pregnant while taking study  drug).  Should 
a female subject (or the female partner of a male subject) become pregnant during 
the study , the subject will inform the Investigator.  The subject will be asked to 
follow up with the study site to report the eventual outcome of the pregnancy .  
This information will be tracked by [CONTACT_70592] y.
Lactation exposure (subject was taking stud y drug while nursing an infant )
Accidental exposure (someone other than the study  subject was exposed to study  
drug)
Overdose (subject received more than the prescribed dose of study drug within a 
given timeframe)
Other medication errors that potentially  place subjects at a greater risk of harm 
than was previously  known or recognized (e.g., study  drug was administered 
intramuscularl y instead of 
intravenousl y)
9.[ADDRESS_76954] be recorded in the appropriate section of the eCRF .  To improve the quality  and 
consistency  of AE data, Investigator s should observe the following general guidelines:
Standard medical terminology  should be used rather than colloquial expre ssions or 
abbreviations.  
Whenever possible, the AE should be evaluated and reported as a diagnosis rather 
than as individual signs or symptoms.  If a definitive diagnosis is not possible, the 
individual signs and s ymptoms should be recorded.
If an AE requires a surgical or diagnostic procedure, the illness leading to the 
procedure should be recorded as the AE, not the procedure itself.
Angioedema attacks:  Any angioedema attacks that occur after the first dose of 
study  drug will be recorded as an AE or SA E, as appropriate.
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76955] access to all records necessary  to ensure integrity  of the data and will 
periodicall y review the progress of the stud y with the P rincipal Investigator .
Frequent communication between the study  site and the Sponsor is essential to ensure that the 
study  is adequately  monitored for safety .  The Investigator will make all appropriate safet y 
assessments (e.g., AEs, clinical laboratory  tests, vital signs, results from physical 
examinations) on an ongoi ng basis.  The Sponsor’s medical monitor will review safety 
information from all study sites as it becomes available throughout the study.   
11.0 DATA HANDLING
Site staff will enter data into a 21 C FRPart 11 compliant eCRF built and programmed by 
[CONTACT_70593].  Data will be reviewed via programmed edit checks triggered 
by [CONTACT_70594]’s Clinical 
Data Management group according to current standard operating procedures (SOPs).  Data 
discre pancies found during data review will be resolved through queries created within the 
eCRF database (automatic or manual) and answered by [CONTACT_6624].  Coding of medical 
terms/conditions and medications will be performed by  [CONTACT_70595] ’s Medical Coding 
Group utilizing the versions of the MedDRA and WHO Drug dictionaries currentl y at use by 
[CONTACT_10188] V IROPHARMA at the time of the study .
Only  individuals with the appropriate user role and training will be granted access to the 
eCRF.  All training must be docum ented and tracked via Shire VIROPHARMA’s SOP and 
electronic database training policy .  Database security  is maintained by [CONTACT_2224] a unique 
username [CONTACT_70607], along with user verification 
checks at set intervals.  All database user administration is performed by [CONTACT_70596]’s eCRF Support Group.  Database hosting services will be performed by [CONTACT_70597].  For Study  0624-301, eCRF software and hosting services will be 
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 74 CONFIDENTIALprovided by [CONTACT_70598], [LOCATION_001].  Validation certificates for software vendors are 
on file at Shire V IROPHARMA .
At database lock, all user roles will be changed to ‘read only’ and no further updates to the 
database will be allowed.  Database close -out documentation will be created by [CONTACT_70596]’s eCRF Support Group and compact discs containing subject data entered into 
the database will be sent to each site’s primary  Investigator .  
12.[ADDRESS_76956] the study  in accordance with the ethical 
principles stated in the Declaration of Helsinki and in compliance with the International 
Conference on Harmonisation (ICH) Tripartite Guideline for Good Clinical Practice and 
applicable regulatory  requirements.
13.[ADDRESS_76957] CONFIDENTIA LITY
Investigator and his/her staff will be required to manage patient data collected for the study  in 
accordance with applicable laws and regulations on personal data protection.  
Monitors, auditors and other authorized representatives of Shire VIROPHARM A, the IRA
approving the study , as well as any applicable regulatory  authorities, will be granted access to 
the study  patients' original medical records for permitted study  purposes, in accordance with 
applicable laws and regulations.  In any presentation of study  results at meetings or in 
publications, subject identity  will remain confidential.
14.0 INFORMED CONSENT
The ICH has issued guidelines to provide protection for human subjects in clinical 
investigations.  The ICH Tripartite Guideline for Good Clinical Practice establishes the 
general requirements for informed consent.  Legal age for consent to treatments or procedures 
involved in clinical investigations is defined under the applicable law of the jurisdiction in 
which the clinical investigation will be c onducted.
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 75 CONFIDENTIALA properl y executed, written permission statement (i.e., informed consent) shall be obtained 
from each parent/legal guardian and assent shall be obtained from the child (to the extent that 
is compatible with the subject’s understanding) prior tothe subject entering the trial, or prior 
to performing any unusual or non-routine procedure that involves a risk to the subject.  The 
permission statement must meet all of the required elements of informed consent.  A separate 
assent form should be prepar ed which explains in very  general terms the purpose of the study , 
what will be expected of or done to the child, and what risks or discomforts may be 
experienced.  A copy of the written permission statement document and assent form to be 
used will be revie wed and approved by [CONTACT_1034].  The document(s) will then be submitted 
to the IRA for review and approval prior to the start of the study .  The Investigator shall 
provide a copy of the signed and dated permission statement and assent form to the 
parent/l egal guardian and a copy  shall be maintained in the subject’s medical record.  The 
Investigator, or his/her designee, must document in the case history  that informed 
consent/assent was obtained prior to study  participation.  If assent was not obtained, this 
should be recorded in the consent form signed by [CONTACT_7903]/legal representative and the 
Investigator, with the reason(s).
All procedures and documentation required for obtaining parental/legal guardian permission 
and assent should be in compliance with ICH guidelines, FDA regulations, and local IRA 
requirements, as well as state and local law.  
15.0 INDEPENDENT REVIEWIN G AUTHORITY APPROVAL
The IRA is the review panel that is responsible for ensuring the protection of the rights, 
safet y, and well -being of human subjects involved in a clinical investigation.  An IRA that is 
adequatel y constituted to provide assurance of that protection will be utilized by [CONTACT_70599] y.
The IRA will be provided with all appropriate material , including a copy  of the informed 
consent /assent for review.  The trial will not be initiated at an investigational site until written 
approval of the research plan and the informed consent /assent document is obtained from the 
appropriate IRA and copi[INVESTIGATOR_70531] .  
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 76 CONFIDENTIALAppropriate reports on the progress of this study will be made to the IRA in accordance with 
applicable government regulations and in agreement with policy  established by  [CONTACT_1034].
16.0 PUBLICATION POLICY
Investigator’s right to publish study  results is addressed in the clinical trial agreement between 
Investigator and Sponsor.  
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 77 CONFIDENTIAL17.0 INVESTIGATOR'S STATE MENT ( PROTOCOL 0624 -301)
A Phase 3, Multicenter, Randomized, Single -blind , Dose -ranging, Crossover Study to 
Evaluate the Safety and Efficacy of Intravenous Administration of CINRYZE®
(C1esterase inhibitor [human]) for the Prevention of Angioedema Attacks in Children 
6 to11Years of age With Hereditary Angioedema.
In conducting this clinical trial, I  agree to b e responsible for:
1.Ensuring that the clinical investigation is conducted according to the signed Form 
FDA 1572 Statement of Investigator (applies to all studies conducted under a US 
IND).
2.Protecting the rights, safety ,and welfare of subjects under my  care .
3.Controlling the drugs and biological products under investigation.
I also agree to conduct the trial as outlined in the protocol and in accordance with Shire 
VIROPHARMA guidelines and all applicable government regulations.  These guidelines and 
regulatio ns include, but are not limited to:
4.Permission to allow Shire VIROPHARMA (or its designee) and FDA, or other regulatory 
agencies, to inspect study  facilities and pertinent records at reasonable times and in a 
reasonable manner, which ensures subject confid entiality .  If I am notified that this 
study  is to be inspected by a regulatory  agenc y, I  will notify  Shire VIROPHARMA as 
soon as possible thereafter (no later than 1 week).
5.Submission of the proposed clinical investigation, including the protocol and informed 
consent /assent form, to a duly  constituted Independent Reviewing Authority  (IRA) for 
approval, and acquisition of written approval for each, prior to the use of the study 
drug.
6.Obtaining written informed consent/assent only after ensuring that the subject , or 
his/her legal representative, is competent to make the decision, understands what is 
contained in the informed consent/assent document, and is consenting voluntarily .  
Written informed consent/assent will be obtained prior to administration of study drug 
or an y non -routine procedures that involve risk; the document contains all the essential 
elements of consent and has been previously  approved by [CONTACT_70600].  
Reference of such will be provided in source documentation.
7.Submission of any proposed protocol amendment to the IRA.  If the protocol 
amendment change(s) increase risk to the study population, or adversely affect the 
validity  of the clinical investigation or the subject's rights, full IRAwritten approval 
must be obtained prior to implementation.  For changes that do not involve increased 
risk or affect the validity  of the investigation or the subject's rights, prior IR Aapproval 
may be obtained by  [CONTACT_70601].
8.Adherence to the study  protocol.  For potential inclusion/exclusion criteria protocol 
deviations, submission for approval to Shire VIROPHARMA prior to enrollment of study 
CINRYZE® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76958]-enrollment protocol 
deviations will be recorded on the appropriate eCRF page or provided in letters to 
Shire V IROPHARMA.
9.Notification to Shire VIROPHARMA of all serious adverse events, regardless of 
relationship to study  drug, as specified in the protocol.  Notification to the IRAof 
serious adverse events as specified in the protocol and per additi onal guidelines as 
provided b y the IR A.
10.Notification to IRA of all unanticipated problems within timeframes provided by [CONTACT_70602].  Unanticipated problems may include any incident, experience, or outcome that 
meets allof the following criteria: (1) unexpect ed (in terms of nature, severit y); (2) 
related or possibly  related to participation in the study ;(3) and suggests that the 
research places subjects or others at a greater risk of harm (including physical, 
psychological, economic, or social harm) than was previously  known or recognized.
11.Provision of adequate trial oversight by [CONTACT_70603], including, but not limited to: allotting sufficient time to properly 
conduct and complete the trial within the agreed upon time period; having available an 
adequate number of qualified staff and adequate facilities for the expected duration of 
the trial and to conduct the trial properly  and safel y; and ensuring that all persons 
assisting with the trial are adequately  informed abou t the protocol, the investigational 
product(s), and are capable of performing their trial related duties and functions.  
Qualifications of individuals assigned responsibility  for the administration of the 
investigational product will be compliant with state and local law or national 
regulations, as applicable.
12.Submission of timely  progress reports to the IRAand Shire VIROPHARMA at 
appropriate intervals not to exceed 1 year and submission of a final report to the IRA
within 3 months after the completion, termination, or discontinuation of the clinical 
investigation. 
13.Maintenance of accurate source records from which case reports are based as well as 
drug accountability  records that show the receipt and disposition (on an overall and 
per subject basis) of allstudy  drug(s) shipped to the Investigator by [CONTACT_70596].
In addition, I agree to provide all the information requested in the eCRF presented to me by 
[CONTACT_70604] y following the completion guidelines provided as part of the 
eCRF .
If I opt to terminate, the foregoing shall equall y apply.
Investigator’s Name (Please Print)
Investigator’s Signature [CONTACT_70608]® (C1esterase inhibitor [human] )
Protocol [ADDRESS_76959] OFREFERENCES
Agostoni and Cicardi, 1992.
Agostoni A, Cicardi M. Hereditary  and acquired C1-inhibitor deficiency: biological and 
clinical characteristics in 235 patients. Medicine (Baltimore) . 1992; 71(4):206-215.
Agostoni et al., 1980.
Agostoni A, Bergamaschini L, Martignoni G, Cicardi M, Marasini B. Treatment of acute 
attacks of hereditary  angioedema with C1-inhibitor concentrate. Ann Allergy . 1980; 
44(5):299-301.
Bergamaschini et al., 1983.
Bergamaschini L, Cicardi M, Tucci A, et al. C1 INH concentrate in the therap y of 
hereditary angioedema. Allergy . 1983; 38(2):81 -84. 
Bork et al., 2000.
Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W. Asphy xiation by [CONTACT_70605]. Mayo Clin Proc . 2000; 75(4):349 -354. 
Bork et al., 2006.
Bork K, Meng G, Staubach P, Hardt J. Hereditary  angioedema: new findings concerning 
symptoms, affec ted organs, and course . Am J Med . 2006; 119(3):267 -274. 
Caballero, 2012.
Caballero T. Angio- oedema due to hereditary  C1 inhibitor deficiency  in children.  Allergol 
Immunopathol (Madr).   2012; Mar 12. [Epub ahead of print]
Frank et al., 1976.
Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and 
its management. Ann Intern Med . 1976; 84(5):[ADDRESS_76960] G, Varga L, Visy B. Clinical management of hereditar y 
angio -oedema in children. Pediatr Allergy Immunol. 2002; 13(3):153 -161.
Farkas et al., 2007.
Farkas H, Jakab L, Temesszentandrási G, et al. Hereditary  angioedema: a decade of human 
C1-inhibitor concentrate therap y. J Allergy Clin Immunol. 2007; 120(4):941 -947.
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 80 CONFIDENTIALGadek et al., 1980.
Gadek JE, Hosea SW, Gelfand JA, et al. Replacement therap y in hereditary  angioedema: 
successful treatment of acute epi[INVESTIGATOR_70532] C1 inhibitor. N 
Engl J Med. 1980; 302(10):542-546.
Gompels et al., 2005.
Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency : consensus document . 
Clin Exp Immunol. 2005; 139:379-394.
Logan and Greaves, 1984.
Logan RA, Greaves MW. Hereditary  angio-oedema: treatment with C1 esterase inhibitor 
concentrate. J R Soc Med. 984; 77(12):1046 -1048. 
Lumry et al., 2013.
Lumry  W, Manning ME, Hurewitz DS, et al. Nanofiltered C1-esterase inhibitor for the 
acute management and prevention of hereditary angioedema attacks due to C1-inhibitor 
deficiency  in children. J Pediatr. 2013; 162(5):1017 -1022.
Noyes and Edwards, 2011.
Noyes J, Edwards RT. EQ-5D for the assessment of health -related quality  of life and 
resource allocation in children: a systematic methodological review. Value Health. 2011; 
14(8):1117-1129.
Nzeako et al., 2001.
Nzeako UC, Frigas E, Tremaine WJ. Hereditary  Angioedema: a broad review for 
clinicians. Arch Intern Med. 2001; 161(20):2417-2429.
Späth et al., 1984.
Späth PJ, Wüthrich B, Bütler R. Quantification of C1-inhibitor functional activities by 
[CONTACT_70606] -evidence of a 
functionally  critical level of C1 -inhibitor concentration. Complement. 1984; 1(3):147 -159.
Wall and Frank, 1990.
Wall RT, Frank M. Reply , Use of purified C1 esterase inhibitor in patients with hered itary 
angioedema. Anesthesiology . 1990; 72(5):957.
Wahn et al., 2012.
Wahn V, Aberer W, Eberl W, et al. Hereditary angioedema (HAE) in children and 
adolescents –a consensus on therapeutic strategies. Eur J Pediatr. 2012; 171(9):[ADDRESS_76961] tes AT, Rosen FS, Frank MM. Treatment of hereditary  angioedema with a vapor -
heated C1 inhibitor concentrate. N Engl J Med. 1996; 334(25):1630-1634.
CINRYZE® (C1esterase inhibitor [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 81 CONFIDENTIALZuraw, 2003.
Zuraw BL. Diagnosis and management of hereditary  angioedema: an American approach .  
Transfus Apher Sci . 2003; 29(3):239 -245.
Zuraw, 2008.
Zuraw BL. Hereditary  angioedema: a current state-of-the-art review, IV: short -and long-
term treatment of hereditary  angioedema: out with the old and in with the new? Ann 
Allergy Asthma Immunol . 2008; 100([ADDRESS_76962] 2):S13- S18.
CINRYZE® (C1esterase inhibitor [human])
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 82 CONFIDENTIALAPPENDIX I : PROCESSING OF SAMPLE S FOR ANALYSES OF 
C1INH ANTIGEN, C1 INH FUNCTIO N, 
C4COMPLEMENT, AND C1 INH ANTIBOD IESIN 
HUMAN PLASMA
Plasma samples will be analyzed for C1 INH antigen, functional C1 INH, C4 complement, 
and antibodies to C1INH according to time points in Schedules 2, 3, 4and 5.  Details of the 
methods and results will be provided i
n the clinical study  report.  Samples for these analyses 
will be collected as follows:
1.A total of 4mL of venous blood will be collected via venipuncture or through an 
indwelling venous catheter into pre-chilled K3EDTA -tubes at each sampling time 
point.  
If an indwelling catheter with a heparin lock is used to collect the sample, first 
flush the line, collect [ADDRESS_76963] the tubes on wet ice until the samples can be centrifuged.  Centrifuge 
the samples at 1800 to 2000 times gravit y(at 4ºC if possible) for 15 ± 2 minutes.  
Immediately  transfer the resulting plasma as follows :
Transfer theplasma equally  between the 2pre-chilled plastic transfer tubes.  
Carefull y remove the plasma from the cells, avoiding contamination of plasma 
with white cells or platelets, since these may contribute enzy mes that will 
falsel y elevate measurements.  Tubes should be appropriatel y labeled using 
labels supplied by  [CONTACT_1034].
The plasma must be stored frozen at −70ºC or colder ideally  within 
30minutes of collection.  If necessary , samples can be stored on slushy  ice for 
up to but 
not exceeding [ADDRESS_76964] thaw.
All deviations to the collection proced ures should be recorded and be included 
in the documentation with the sample shipment to the anal ytical laboratory . 
All shippi[INVESTIGATOR_70533] a separate laboratory  manual. 
CAUTION!   Samples for complement testing are sensitive to cold inactivation.  
Samples must be stored at −70°C or colder.  
CINRYZE® (C1esterase inhibitor [human])
Protocol [ADDRESS_76965] will be shipped frozen on dry ice to the analytical 
laboratory  using shippi[INVESTIGATOR_70534].  The other set of samples will 
be stored frozen at −70°C or below and shipped to the laboratory  following the 
schedule/instructions provided in the laboratory  manual.
All samples will be analy zed within the established stability  for the samples and will be 
properl y disposed of after they have exceeded their established stability . 
CINRYZE® (C1esterase inhibito r [human] )
Protocol 0624 -301 w ith Amendments 1 , 2,3, and 4
26 January 2015 84 CONFIDENTIALAPPENDIX II: RECOMMENDED PROCEDUR ES FOR SUSPECTED VEN OUS THROMBOEMBOLISM 
OR OTHER THROMBOTIC OR THROMBOEMBOLIC EV ENTS
